[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 527
1. Murtoniemi K, Pirinen E, Kähkönen M, Heiskanen N, Heinonen S: Smooth muscle tumor of the placenta - an entrapped maternal leiomyoma: a case report. J Med Case Rep; 2009;3:7302

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle tumor of the placenta - an entrapped maternal leiomyoma: a case report.
  • INTRODUCTION: Neoplasms of the placenta are uncommon.
  • Tumors arising from the placental tissue include two distinct histological types: the benign vascular tumor, chorangioma, and very rarely, choriocarcinoma.
  • Benign leiomyomas, in contrast, are very common tumors of the uterine wall and occur in 0.1% to 12.5% of all pregnant women.
  • This case is possibly the first report on this kind of a placental tumor which has been examined using both immunohistochemistry and chromosome analysis.
  • CASE PRESENTATION: A 34-year-old G4P3 Caucasian woman was followed up antenatally because of a stillbirth in her previous pregnancy.
  • Histologically, the tumor was a benign leiomyoma and this finding was supported by immunohistochemistry.
  • Chromosomes of the neoplasm were studied by the fluorescence in situ hybridization technique and the tumor was found to carry XX chromosomes.
  • CONCLUSION: A rare benign smooth muscle neoplasm involving the placental parenchyma is presented.
  • The tumor was a uterine leiomyoma of maternal origin, which had become entrapped by the placenta.
  • This case report is of interest to the clinical specialty of obstetrics and gynecology and will advance our knowledge of the etiology of placental tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Indian J Pathol Microbiol. 2005 Apr;48(2):223-4 [16758675.001]
  • [Cites] Obstet Gynecol Surv. 2005 Feb;60(2):132-8 [15671902.001]
  • [Cites] Am J Surg Pathol. 1998 Mar;22(3):355-9 [9500778.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1991;419(4):309-15 [1949613.001]
  • [Cites] Virchows Arch. 2000 Feb;436(2):167-71 [10755608.001]
  • [Cites] South Med J. 1985 Jul;78(7):863-4 [4012385.001]
  • [Cites] J Reprod Med. 2001 Oct;46(10):937-40 [11725743.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jul;20(3):284-8 [11444205.001]
  • [Cites] Histopathology. 2000 Sep;37(3):287-9 [10971709.001]
  • [Cites] Gynecol Oncol. 1989 Apr;33(1):108-11 [2649418.001]
  • (PMID = 19830174.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2726536
  •  go-up   go-down


2. Huang J, Loh KS, Petersson F: Epstein-barr virus-associated smooth muscle tumor of the larynx: report of a rare case mimicking leiomyosarcoma. Head Neck Pathol; 2010 Dec;4(4):300-4
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-barr virus-associated smooth muscle tumor of the larynx: report of a rare case mimicking leiomyosarcoma.
  • We present a patient (male 54 years) with a history of renal transplant who 14 years post transplantation developed a symptomatic (stridor) laryngeal Epstein Barr virus (EBV)-associated smooth muscle tumor (EBV-SMT) in the absence of concomitant disease elsewhere.
  • Nine years post transplantation the patient developed a subcutaneous EBV-SMT tumor located on the calf.
  • The laryngeal tumor displayed low-grade nuclear atypia and was infiltrating into the surrounding soft tissue, focally ulcerating through the overlying epithelium.
  • Histologic features included: neoplastic cells with myoid differentiation, a component of primitive appearing small mesenchymal cells with hyperchromatic nuclei, mitotic activity, intralesional small to medium sized blood vessels and T-lymphocytes.
  • Both the myoid and small cell mesenchymal components strongly expressed smooth muscle actin and h-caldesmon, but not desmin, cytokeratins, CD34 or S-100 protein.
  • No other tumor was detected on clinical and radiological examinations and no evidence of tumor in other sites, over 8 months of follow-up, till death was detected.
  • This case emphasizes the importance of considering this pathologic entity when solitary smooth muscle actin-expressing tumors are encountered in the larynx of immunocompromised patients.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / virology. Leiomyosarcoma / pathology
  • [MeSH-minor] Biopsy. Diagnosis, Differential. Humans. Kidney Transplantation. Larynx / pathology. Larynx / radiography. Male. Middle Aged. Muscle, Smooth / pathology. Muscle, Smooth / radiography. Muscle, Smooth / virology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otolaryngol. 2005 May-Jun;26(3):201-6 [15858778.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):75-82 [16330945.001]
  • [Cites] J Laryngol Otol. 2006 Feb;120(2):e3 [16372993.001]
  • [Cites] Hum Pathol. 2007 Sep;38(9):1293-304 [17707260.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):614-21 [10757411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1974 Dec;71(12):4737-41 [4373728.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):12-8 [7990860.001]
  • [Cites] N Engl J Med. 1995 Jan 5;332(1):19-25 [7990861.001]
  • [Cites] J Laryngol Otol. 1995 Jan;109(1):77-9 [7876748.001]
  • [Cites] Am J Surg Pathol. 1995 Aug;19(8):859-72 [7611533.001]
  • [Cites] N Engl J Med. 1995 Sep 14;333(11):693-8 [7637746.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] J Laryngol Otol. 2008 Jan;122(1):100-4 [17445307.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2008;70(4):264-7 [18487903.001]
  • [Cites] Ear Nose Throat J. 2008 May;87(5):283-7 [18572786.001]
  • [Cites] J Cutan Pathol. 2010 Apr;37(4):507-10 [19615017.001]
  • [Cites] Head Neck. 2010 Nov;32(11):1573-8 [19787794.001]
  • (PMID = 20690046.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2996495
  •  go-up   go-down


3. Fujishiro M: Endoscopic submucosal dissection for stomach neoplasms. World J Gastroenterol; 2006 Aug 28;12(32):5108-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic submucosal dissection for stomach neoplasms.
  • Recent advances in techniques of therapeutic endoscopy for stomach neoplasms are rapidly achieved.
  • ESD is a new endoscopic technique using cutting devices to remove the tumor by the following three steps: injecting fluid into the submucosa to elevate the tumor from the muscle layer, pre-cutting the surrounding mucosa of the tumor, and dissecting the connective tissue of the submucosa beneath the tumor.
  • So the tumors are resectable in an en bloc fashion, regardless of the size, shape, coexisting ulcer, and location.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Gastrectomy / instrumentation. Gastroscopy / methods. Intestinal Mucosa / pathology. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2004 Jul;36(7):579-83 [15243878.001]
  • [Cites] Endoscopy. 2004 Apr;36(4):306-12 [15057679.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):788-801 [15326574.001]
  • [Cites] Gastrointest Endosc. 1988 May-Jun;34(3):264-9 [3391382.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):58-62 [8454147.001]
  • [Cites] World J Surg. 1997 Sep;21(7):694-701 [9276699.001]
  • [Cites] Gastrointest Endosc. 1998 Nov;48(5):550-4; discussion 554-5 [9831855.001]
  • [Cites] Surgery. 1999 Feb;125(2):148-54 [10026747.001]
  • [Cites] Gastrointest Endosc. 1999 Aug;50(2):251-6 [10425422.001]
  • [Cites] J Clin Oncol. 2005 Jul 10;23(20):4490-8 [16002839.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S67-70 [16013002.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7 Suppl 1):S71-3 [16013003.001]
  • [Cites] Gastrointest Endosc. 2005 Dec;62(6):933-42 [16301040.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):243-9 [16427929.001]
  • [Cites] Gastrointest Endosc. 2006 Apr;63(4):596-601 [16564858.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):412-5 [16680644.001]
  • [Cites] J Clin Gastroenterol. 2006 May-Jun;40(5):378-84 [16721217.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):688-94 [16713746.001]
  • [Cites] Endoscopy. 2006 May;38(5):493-7 [16767585.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Oct;21(10):1586-9 [16928221.001]
  • [Cites] Gut. 2001 Feb;48(2):225-9 [11156645.001]
  • [Cites] Endoscopy. 2001 Mar;33(3):221-6 [11293753.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):62-6 [11427843.001]
  • [Cites] Gastrointest Endosc. 2002 Apr;55(4):576-81 [11923778.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):507-12 [12297765.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):513-6 [12297766.001]
  • [Cites] Endoscopy. 2002 Nov;34(11):935 [12430083.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):690-4 [12929067.001]
  • [Cites] Endoscopy. 2004 Jul;36(7):584-9 [15243879.001]
  • (PMID = 16937520.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] China
  • [Number-of-references] 47
  • [Other-IDs] NLM/ PMC4088006
  •  go-up   go-down


Advertisement
4. Esmaeilzadeh M, Tavakolli A, Safaei A: Recurrent intracardiac leiomyomatosis. Can J Cardiol; 2007 Nov;23(13):1085-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An intravenous leiomyoma, a histologically benign smooth muscle tumour, arises from either a uterine myoma or the walls of a uterine vessel, with extension into veins.
  • [MeSH-major] Heart Neoplasms / secondary. Leiomyomatosis / ultrasonography. Smooth Muscle Tumor / ultrasonography. Uterine Neoplasms / ultrasonography
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med. 1980 Sep;69(3):471-5 [7416191.001]
  • [Cites] N Engl J Med. 1980 Oct 30;303(18):1043-4 [7421892.001]
  • [Cites] Cardiovasc Surg. 1995 Dec;3(6):693-6 [8745195.001]
  • [Cites] Pathol Annu. 1988;23 Pt 2:153-83 [3060811.001]
  • [Cites] Am Heart J. 1987 Jan;113(1):171-8 [3541555.001]
  • (PMID = 17985013.001).
  • [ISSN] 0828-282X
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2651934
  •  go-up   go-down


5. Kelesidis T: Smooth muscle tumour of the right groin: description of a unique case. Ir J Med Sci; 2010 Dec;179(4):603-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle tumour of the right groin: description of a unique case.
  • INTRODUCTION: A deep soft tissue smooth muscle tumour is a rare entity with few cases described in the literature.
  • MATERIALS AND METHODS: Herein, we report a case of a smooth muscle tumour of the right inguinal area which presented as a painful mass.
  • This case is unique because of the anatomic location of the tumour, which has not been reported before, and the clinical presentation of this tumour mimicked a hernia.
  • CONCLUSION: Smooth muscle tumours in the inguinal area are an exceptionally rare occurrence, but clinicians should always consider less routine causes for a painful inguinal mass.
  • [MeSH-major] Inguinal Canal / pathology. Muscle, Smooth / pathology
  • [MeSH-minor] Adult. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Female. Humans. Immunohistochemistry. Prognosis. Smooth Muscle Tumor / drug therapy. Smooth Muscle Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825475.001).
  • [ISSN] 1863-4362
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal
  •  go-up   go-down


6. Murakami M, Uehara H, Nishimura M, Iwasa T, Ikawa H: A huge ovarian smooth muscle tumor: a case report. J Med Invest; 2010 Feb;57(1-2):158-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A huge ovarian smooth muscle tumor: a case report.
  • Ovarian smooth muscle tumors are a very rare type of ovarian tumor.
  • In this paper, we report the case of a 62-year-old woman who had a huge smooth muscle tumor of the right ovary.
  • The values of all the serum tumor markers were within normal limit.
  • The tumor measured 25 cm in diameter and weighed 6,200 g.
  • According to the criteria for the evaluation of the uterine smooth muscle tumors, this huge tumor was diagnosed as atypical leiomyoma.
  • However, we finally made a diagnosis of this tumor as a smooth muscle tumor of uncertain malignant potential (STUMP) because of its huge size.
  • Further information is required regarding the characteristics of ovarian smooth muscle tumor and the propriety to introduce uterine tumor histological criteria to ovarian tumors.
  • [MeSH-major] Ovarian Neoplasms / pathology. Smooth Muscle Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20299756.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Arumilli BR, Lenin Babu V, Paul AS: Painful swollen leg--think beyond deep vein thrombosis or Baker's cyst. World J Surg Oncol; 2008;6:6
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The diagnosis of deep vein thrombosis of leg is very common in clinical practice.
  • CASE PRESENTATION: This is a report of three patients who presented with a painful swollen leg and were initially treated as a deep vein thrombosis or a baker's cyst, but later diagnosed as a pleomorphic sarcoma, a malignant giant cell tumor of the muscle and a myxoid liposarcoma.
  • CONCLUSION: A painful swollen leg is a common clinical scenario and though rare, tumors must be thought of without any delay, in a duplex negative, low risk deep vein thrombosis situation.
  • [MeSH-major] Liposarcoma / diagnosis. Muscle Neoplasms / diagnosis. Popliteal Cyst / diagnosis. Sarcoma / diagnosis. Venous Thrombosis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Leg / blood supply. Male. Middle Aged

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] ANZ J Surg. 2004 Sep;74(9):820-2 [15379828.001]
  • [Cites] Circulation. 1989 Apr;79(4):810-4 [2647319.001]
  • [Cites] Am J Surg. 1993 Aug;166(2):211-5 [8394661.001]
  • [Cites] Clin Chem. 2004 Jul;50(7):1136-47 [15142977.001]
  • [Cites] J Thromb Haemost. 2003 Apr;1(4):645-51 [12871396.001]
  • [Cites] Clin Rheumatol. 2003 May;22(2):149-53 [12740683.001]
  • [Cites] Cardiovasc Surg. 1996 Aug;4(4):505-8 [8866090.001]
  • [Cites] Skeletal Radiol. 1981;6(3):157-63 [7268459.001]
  • [Cites] J Vasc Surg. 1997 Apr;25(4):658-62 [9129621.001]
  • [Cites] Lancet. 2005 Mar 26-Apr 1;365(9465):1163-74 [15794972.001]
  • [Cites] CMAJ. 2006 Oct 24;175(9):1087-92 [17060659.001]
  • [Cites] J Ultrasound Med. 2006 Dec;25(12):1615-8 [17121961.001]
  • [Cites] Postgrad Med J. 2002 Dec;78(926):742-5 [12509692.001]
  • [Cites] Srp Arh Celok Lek. 2001 Jan-Feb;129(1-2):13-7 [11534278.001]
  • [Cites] J Emerg Med. 2000 Oct;19(3):225-30 [11033266.001]
  • (PMID = 18205917.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2244628
  •  go-up   go-down


8. Dramis A, Grimer RJ: Angioleiomyoma: a rare cause of fixed flexion contracture of the elbow. Sarcoma; 2006;2006:93569

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe an unusual case of a patient presented with a painless fixed flexion contracture of the elbow due to an angioleiomyoma.
  • This benign smooth muscle tumour should be considered in the differential diagnosis of flexion contractures of the elbow.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Jul 1;54(1):126-30 [6722737.001]
  • [Cites] Int J Clin Pract. 2004 Jun;58(6):587-91 [15311559.001]
  • (PMID = 17251661.001).
  • [ISSN] 1357-714X
  • [Journal-full-title] Sarcoma
  • [ISO-abbreviation] Sarcoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  • [Other-IDs] NLM/ PMC1698144
  •  go-up   go-down


9. Clauss S, Höller S, Hegi L, Blum R, Hösli I: ["STUMP" (smooth muscle tumour of uncertain malignant potential), a tumour of the uterus in pregnancy--a diagnostic and therapeutic challenge]. Z Geburtshilfe Neonatol; 2010 Apr;214(2):74-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["STUMP" (smooth muscle tumour of uncertain malignant potential), a tumour of the uterus in pregnancy--a diagnostic and therapeutic challenge].
  • [Transliterated title] "STUMP" (smooth muscle tumor of uncertain malignant potential), ein Uterustumor in der Schwangerschaft, eine diagnostische und therapeutische Herausforderung.
  • We present the case of a preterm birth in the 27 (th) week of gestation, probably due to a chorionamnionitis, with the coincidental finding of a STUMP (smooth muscle tumour of uncertain malignant potential).
  • The STUMP is a rare tumour entity characterised by smooth muscle cells which is difficult to classify by means of histology.
  • The WHO classification of mesenchymal tumours allocates STUMP as an intermediate tumour between a benign leiomyoma and a malignant leiomyosarcoma.
  • If histological criteria of malignancy are not fulfilled because the type of necrosis is in doubt or the interpretation of mitotic figures is ambiguous and the tumour cannot reliably be classified as a leiomyoma, it is classified as a STUMP.
  • Compared to malignant leiomyosarcoma, STUMP has a superior prognosis, but the biological potential of the tumour remains unclear; lymphogenic and haematogenic dissemination seems possible even after a long period of time.
  • STUMP represents a challenge in diagnosis and treatment recommendations.
  • We present the first description of a case of STUMP during pregnancy, raising the question of whether the histological finding in tumours of the uterus during pregnancy are important.
  • [MeSH-major] Smooth Muscle Tumor / diagnosis. Smooth Muscle Tumor / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy

  • Genetic Alliance. consumer health - Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20411475.001).
  • [ISSN] 1439-1651
  • [Journal-full-title] Zeitschrift für Geburtshilfe und Neonatologie
  • [ISO-abbreviation] Z Geburtshilfe Neonatol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Gan EC, Lau DP, Chuah KL: Epstein-Barr virus-associated smooth muscle tumour mimicking bilateral vocal process granuloma. J Laryngol Otol; 2008 Jan;122(1):100-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated smooth muscle tumour mimicking bilateral vocal process granuloma.
  • A case is presented of a 36-year-old Chinese woman with a renal transplant for end-stage renal failure due to Goodpasture's syndrome.
  • Histological and immunohistochemical staining was consistent with Epstein-Barr virus-associated smooth muscle tumour.
  • This is believed to be the first reported case in the English literature of such a tumour affecting the vocal process.
  • The aim of this paper is to present the pathogenesis, clinical behaviour and treatment of Epstein-Barr virus-associated smooth muscle tumour, and to review the literature concerning the differential diagnosis of polypoid vocal process lesions.
  • [MeSH-major] Epstein-Barr Virus Infections / complications. Granuloma / diagnosis. Laryngeal Diseases / diagnosis. Opportunistic Infections / complications. Smooth Muscle Tumor / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Kidney Transplantation / immunology. Laryngeal Neoplasms / diagnosis. Laryngeal Neoplasms / virology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Tomography, X-Ray Computed. Vocal Cords

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445307.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Thong JF, Chuah KL: EBV-associated smooth muscle tumour presenting as a parapharyngeal mass--a rare presentation. Auris Nasus Larynx; 2009 Feb;36(1):120-2
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated smooth muscle tumour presenting as a parapharyngeal mass--a rare presentation.
  • The Epstein-Barr virus-associated smooth muscle tumour (EBV-SMT) is a rare entity that has only recently been recognised.
  • [MeSH-major] Epstein-Barr Virus Infections / virology. Pharyngeal Neoplasms / virology. Smooth Muscle Tumor / virology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Adult. Diagnosis, Differential. Humans. Male. Otitis Media / etiology

  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18486379.001).
  • [ISSN] 1879-1476
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


12. Zámecník M, Staník M: Dedifferentiated mixed stromal-smooth muscle tumor of the uterus. Report of a case. Cesk Patol; 2006 Apr;42(2):81-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated mixed stromal-smooth muscle tumor of the uterus. Report of a case.
  • So-called dedifferentiation in mesenchymal neoplasms of the uterus is very rare.
  • Among conventional low-grade stromal tumors only three cases of dedifferentiation were reported, whereas in mixed stromal-smooth muscle tumors the dedifferentiation was yet not described.
  • Here we present such a case of low-grade mixed stromal-smooth muscle tumor with dedifferentiation.
  • The tumor occurred in 52-years-old postmenopausal patient.
  • The low-grade component with morphology of mixed stromal-smooth muscle tumor was limited to a few peripheral areas of the lesion.
  • This case demonstrates that low-grade mixed stromal-smooth muscle tumor of the uterus can dedifferentiate like a pure stromal tumor.
  • It shows that extensive sampling/histological search may be needed for recognition of a minor component in a dedifferentiated tumor.
  • [MeSH-major] Mixed Tumor, Malignant / pathology. Sarcoma, Endometrial Stromal / pathology. Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cesk Patol. 2006 Jul;42(3):149
  • (PMID = 16715633.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


13. Al-Daraji WI, Salman WD, Nakhuda Y, Zaman F, Eyden B: Primary smooth muscle tumor of the pleura: a clinicopathological case report with ultrastructural observations and a review of the literature. Ultrastruct Pathol; 2005 Sep-Oct;29(5):389-98
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for smooth muscle tumor .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary smooth muscle tumor of the pleura: a clinicopathological case report with ultrastructural observations and a review of the literature.
  • Primary smooth muscle tumor of the pleura is exceptionally rare.
  • The authors describe a primary smooth muscle tumor of the pleura that was discovered incidentally on chest X-ray in a 73-year-old man.
  • Computerized tomography (CT) guided needle cores from the pleura showed a primary smooth muscle tumor of undetermined malignant potential.
  • Further excision of the whole tumor showed an intimate relation to pleura, and the diagnosis of leiomyosarcoma was made.
  • The clinical, radiological, histopathological, immunohistochemical, and ultrastuctural findings were consistent with a primary smooth muscle tumor of the pleura.
  • This is the seventh case in the literature of a primary smooth muscle tumor of the pleura, which, to the best of the authors' knowledge, is the first such case of the pleura to be diagnosed on CT-guided needle biopsy.
  • In conclusion, this method of investigation is recommended since it is minimally invasive but has a rewarding yield in providing the most likely diagnosis, predicting prognosis, and management planning.
  • [MeSH-major] Leiomyosarcoma / pathology. Mediastinal Neoplasms / pathology. Pleural Neoplasms / pathology. Smooth Muscle Tumor / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Thoracotomy. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257865.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


14. Yu L, Aldave AJ, Glasgow BJ: Epstein-Barr virus-associated smooth muscle tumor of the iris in a patient with transplant: a case report and review of the literature. Arch Pathol Lab Med; 2009 Aug;133(8):1238-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-associated smooth muscle tumor of the iris in a patient with transplant: a case report and review of the literature.
  • Epstein-Barr virus infection has been linked to the development of smooth muscle tumors in immunocompromised patients with organ transplants and acquired immunodeficiency syndrome.
  • A 52-year-old female recipient of a renal transplant presented with enlarging masses of the left iris.
  • Incisional biopsy of the mass revealed a smooth muscle tumor of the iris.
  • Epstein-Barr virus infection was confirmed by in situ hybridization for Epstein-Barr virus-encoded, small RNA in tumor cells.
  • Eight months after total iridectomy the patient was free of disease.
  • Although the prognosis and classification of Epstein-Barr virus-associated smooth muscle tumors are controversial, mortalities caused by these tumors are rare.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / virology. Herpesvirus 4, Human / isolation & purification. Iris Neoplasms / virology. Kidney Transplantation. Smooth Muscle Tumor / virology
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Disease-Free Survival. Female. Humans. Immunocompromised Host. In Situ Hybridization. Middle Aged. Postoperative Complications. RNA, Viral


15. Rice TL, Chantler I, Loram LC: Neutralisation of muscle tumour necrosis factor alpha does not attenuate exercise-induced muscle pain but does improve muscle strength in healthy male volunteers. Br J Sports Med; 2008 Sep;42(9):758-62
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neutralisation of muscle tumour necrosis factor alpha does not attenuate exercise-induced muscle pain but does improve muscle strength in healthy male volunteers.
  • OBJECTIVE: Inflammatory mediators, such as tumour necrosis factor alpha (TNFalpha), may contribute to delayed-onset muscle soreness.
  • The effect of neutralising TNFalpha with etanercept, a soluble TNFalpha receptor, on delayed-onset muscle soreness (DOMS) induced in the quadriceps muscle was analysed.
  • Muscle soreness was assessed using a 100-mm visual analogue scale (VAS), and pressure pain threshold (PPT) on the thigh before and 24, 48 and 72 hours after exercise.
  • Changes in the subject's muscle strength were detected by reassessing the subject's 1RM 24, 48 and 72 hours after exercise.
  • RESULTS: Muscle strength decreased 24 and 48 hours after exercise regardless of agent administered (analysis of variance, p<0.001).
  • At 72 hours after exercise, muscle strength was significantly greater (p<0.01) after etanercept than after placebo.
  • CONCLUSION: TNFalpha does not affect muscle soreness associated with unaccustomed exercise, but may improve the recovery of muscle function.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Exercise / physiology. Immunoglobulin G / pharmacology. Muscle Strength / physiology. Muscle, Skeletal / physiology. Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • [MeSH-minor] Adult. Creatine Kinase / blood. Cross-Over Studies. Double-Blind Method. Etanercept. Humans. Male. Pain / etiology. Pain / prevention & control. Pain Measurement. Receptors, Tumor Necrosis Factor. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • Hazardous Substances Data Bank. Etanercept .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717057.001).
  • [ISSN] 1473-0480
  • [Journal-full-title] British journal of sports medicine
  • [ISO-abbreviation] Br J Sports Med
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Tumor Necrosis Factor-alpha; EC 2.7.3.2 / Creatine Kinase; OP401G7OJC / Etanercept
  •  go-up   go-down


16. Samadi DB, Chughtai B, Akhavan A, Guru K, Rehman J: Incidental seminal vesicle smooth muscle neoplasm of unknown malignancy following robotic-assisted laparoscopic prostatectomy. Can J Urol; 2008 Jun;15(3):4109-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental seminal vesicle smooth muscle neoplasm of unknown malignancy following robotic-assisted laparoscopic prostatectomy.
  • Primary soft tissue sarcomas of the genitourinary tract are rarely seen, especially in the seminal vesicle.
  • While sarcomas have been reported in the seminal vesicle, this is the first report of a smooth muscle neoplasm, of uncertain malignant potential, involving the seminal vesicle.
  • The finding was incidental, following robotic-assisted radical retropubic prostatectomy for prostate cancer.
  • To our knowledge, this is also the first report of a primary seminal vesicle tumor found following radical prostatectomy.
  • [MeSH-major] Adenocarcinoma / surgery. Genital Neoplasms, Male / diagnosis. Laparoscopy. Neoplasms, Multiple Primary. Prostatectomy. Prostatic Neoplasms / surgery. Robotics. Seminal Vesicles. Smooth Muscle Tumor / diagnosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570719.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


17. Phillips P, Yalcin M, Cui H, Abdel-Nabi HH, Sajjad M, Bernacki R, Mousa S: Effects of novel heparin-derived compounds on tumor uptake of chemotherapeutics and chemoresponse. J Clin Oncol; 2009 May 20;27(15_suppl):2537

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of novel heparin-derived compounds on tumor uptake of chemotherapeutics and chemoresponse.
  • : 2537 Thrombotic complications are the second most common cause of mortality in cancer patients and fibrin deposition in the tumor microenvironment might play a key role in tumor progression and inference with tumor chemotherapeutic uptake.
  • Treatments that target these processes may result in improved uptake of chemotherapeutic agents and subsequent inhibition of tumor growth and metastasis.
  • Tissue Factor (TF) is frequently associated with aggressive behavior and poor outcome in tumors.
  • We have previously demonstrated potent anti-tumor efficacy for various mechanisms that interfere with TF/VIIa.
  • The purpose of this study was to investigate the effects of low molecular weight heparins (LMWH) and sulfated non-anticoagulant LMWH (S-NACH) on tumor chemotherapeutic uptake. STUDIES:.
  • (1) Nude mice xenograft A549 human lung carcinoma: LMWH or S-NACH at 10 mg/kg S.C. daily effectively limited tumor growth. (2) LCC6 human lung tumor xenograft model: Paclitaxel alone or in combination with Tinzaparin or S-NACH on tumor re-growth after discontinuation of treatment: Paclitaxel + S-NACH treatment showed significant (P<0.01) tumor growth suppression and improved survival when compared to Paclitaxel. (3) Biodistribution studies: animals were injected with LMWH S.C. daily for 5 days (10 mg/kg) then injected i.v. with [<sup>124</sup>-I]-Paclitaxel.
  • LMWH increased [<sup>124</sup>-I]-Paclitaxel uptake into LCC6 tumors with tumor: muscle ratios several fold greater than that of [<sup>124-</sup>I]-Paclitaxel alone at 24 hrs post injection.
  • This is a highly significant result in the light of the fact that the FDA criterion for a clinically meaningful effect is a 15% increase in uptake. (4) HPLC studies of tumor uptake of Doxorubicin (DOX in mice treated with 10 mg/kg of LMWH or S-NACH for 10 days followed by Doxorubicin (2.5 mg/kg).
  • Both LMWH and S-NACH significantly (P<0.01) increased the uptake of chemotherapeutic agent DOX in MCF7 DOX resistant tumors by 1.5-2 folds but not in heart or lung tissues, confirming the findings obtained with another agent [<sup>124</sup>-I]-Paclitaxel.
  • Protocols utilizing adjuvant or neo-adjuvant therapy with LMWH or S-NACH could lead to increase tumor chemo responsiveness and overcoming tumor chemo resistance.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961851.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Rigopoulou A, Vlychou M, Ostlere SJ, Gibbons CL, Athanasou NA: A primary leiomyosarcoma of bone containing pseudoepithelial plexiform elements. Skeletal Radiol; 2007 Aug;36(8):791-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rare but distinctive variant of smooth muscle tumours that occurs almost exclusively in the uterus is characterised by the presence of plexiform tumourlets, which are composed of clumps and cords of tumour cells that form a discrete pseudoepithelial component.
  • We report on a case of a primary leiomyosarcoma of the proximal humerus, which, in addition to characteristic histological and immunophenotypic features of leiomyosarcoma, contained plexiform tumourlets.
  • Tumour cells in the plexiform component focally expressed muscle/smooth muscle actin, calponin and cytokeratin.
  • Spindle-shaped and epithelioid smooth muscle tumour cells also expressed the above antigens.
  • This is the first report of a plexiform smooth muscle tumour arising in bone.
  • This case is remarkable, not only for being only the second reported case of a malignant plexiform smooth muscle tumour, but also for being one of very few examples of this type of tumour arising outside the uterus; it also is unique in having arisen in a male patient.
  • This variant of primary leiomyosarcoma needs to be distinguished from other bone tumours containing epithelial elements, notably metastatic carcinoma.
  • [MeSH-major] Bone Neoplasms / diagnosis. Humerus / pathology. Leiomyosarcoma / diagnosis. Neoplasms, Glandular and Epithelial / diagnosis
  • [MeSH-minor] Adult. Biomarkers, Tumor. Biopsy. Diagnosis, Differential. Follow-Up Studies. Fractures, Spontaneous / etiology. Humans. Magnetic Resonance Imaging. Male. Prostheses and Implants. Rare Diseases. Shoulder / pathology. Shoulder / radiography. Shoulder / surgery. Shoulder Fractures / etiology. Shoulder Pain / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483943.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


19. Jiang Y, Tian X, Yuan J, Jin Y, Tan Y: Relationship of adrenomedullin expression and microvessel density and prognosis in smooth muscle tumor of uterus. Front Med China; 2007 Oct;1(4):398-400

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of adrenomedullin expression and microvessel density and prognosis in smooth muscle tumor of uterus.
  • The aim of this paper was to investigate the relationship between the expression of adrenomedullin (ADM) and microvessel density (MVD) and prognosis in smooth muscle tumor of uterus.
  • The ADM is an important angiogenic factor in smooth muscle tumor of uterus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24573933.001).
  • [ISSN] 1673-7342
  • [Journal-full-title] Frontiers of medicine in China
  • [ISO-abbreviation] Front Med China
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Guntupalli SR, Ramirez PT, Anderson ML, Milam MR, Bodurka DC, Malpica A: Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. Gynecol Oncol; 2009 Jun;113(3):324-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis.
  • OBJECTIVE: This retrospective study was designed to evaluate the clinicopathologic features and outcomes of a cohort of patients diagnosed with uterine smooth muscle tumor of uncertain malignant potential (STUMP) seen at a single institution.
  • Variables of interest included age at diagnosis, recurrence rate, and disease-free and overall survival.
  • The mean age at diagnosis was 43 years (range 25-75 years).
  • One of the three patients who had recurrent disease was found to have a leiomyosarcoma at the time of recurrence.
  • All three patients with recurrence were alive and disease-free at a mean follow-up time of 121 months.
  • [MeSH-major] Leiomyosarcoma / pathology. Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Cohort Studies. Disease-Free Survival. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19342083.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA101642
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Salamanca J, Massa DS: EBV-associated hepatic smooth muscle tumor after lung transplantation: report of a case and review of the literature. J Heart Lung Transplant; 2009 Nov;28(11):1217-20
MedlinePlus Health Information. consumer health - Lung Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV-associated hepatic smooth muscle tumor after lung transplantation: report of a case and review of the literature.
  • Post-transplant smooth muscle tumors (PTSMTs) are a rare and recently recognized neoplasm associated with Epstein-Barr virus (EBV).
  • We describe the clinicopathologic, immunohistochemical and molecular features of a new case of EBV-associated PTSMT arising in the liver of a 55-year-old lung transplant recipient for lymphangioleiomyomatosis.
  • To our knowledge, this is the third smooth muscle tumor (the second one proved to be associated with EBV) after lung transplantation.
  • The 2 previous cases are reviewed and the differential diagnosis is also discussed.
  • [MeSH-major] Epstein-Barr Virus Infections / diagnosis. Liver Neoplasms / virology. Lung Transplantation / adverse effects. Lymphangioleiomyomatosis / diagnosis

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19783183.001).
  • [ISSN] 1557-3117
  • [Journal-full-title] The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
  • [ISO-abbreviation] J. Heart Lung Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hammouche S, Mohammed I, Maheswaran T, Douds A: A rare clinical presentation of a malignant fibrous histiocytoma within the iliopsoas muscle. Ann R Coll Surg Engl; 2010 Jan;92(1):W18-20
Genetic Alliance. consumer health - Malignant fibrous histiocytoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare clinical presentation of a malignant fibrous histiocytoma within the iliopsoas muscle.
  • Primary malignant tumours of the iliopsoas compartment are rare clinical entities that are infrequently reported in the literature.
  • Although presenting symptoms vary, this is a very uncommon report of referred pain to the groin and testicular region in a psoas muscle tumour.
  • [MeSH-major] Histiocytoma, Malignant Fibrous / diagnosis. Muscle Neoplasms / diagnosis. Psoas Muscles

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20056053.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. O'Brien J, Loftus B, Barrett C, Torreggiani W: Leiomyoma of the testis: a rare testicular mass. J Clin Ultrasound; 2008 May;36(4):240-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the sonographic appearance of a testicular leiomyoma, which is a rare smooth muscle tumor of the testis.
  • The patient presented with a painless testicular mass that was confirmed as an intratesticular tumor on sonographic examination.
  • [MeSH-major] Leiomyoma / ultrasonography. Testicular Neoplasms / ultrasonography. Ultrasonography, Doppler, Color
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley Periodicals, Inc. J Clin Ultrasound, 2008.
  • (PMID = 18286504.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Huang SE, Huang SC, Lee WY, Hsu KF: Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression. Int J Gynecol Cancer; 2008 Jul-Aug;18(4):851-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meigs' syndrome caused by uterine smooth muscle tumor of uncertain malignant potential with low vascular endothelial growth factor expression.
  • Smooth muscle tumor of uncertain malignant potential (STUMP) presenting as pseudo-Meigs' syndrome with low vascular endothelial growth factor (VEGF) expression has not been reported in previous literature.
  • The final pathologic report revealed a STUMP tumor with low expression of VEGF by immunohistochemistry.
  • Uterine STUMP tumor may cause pseudo-Meigs' syndrome.
  • [MeSH-major] Meigs Syndrome / etiology. Smooth Muscle Tumor / complications. Uterine Neoplasms / complications. Vascular Endothelial Growth Factor A / metabolism
  • [MeSH-minor] Disease Progression. Down-Regulation. Female. Humans. Middle Aged. Pleural Effusion, Malignant / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944915.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


25. Ichikawa H, Taniguchi E, Fujimoto T, Fukumori Y: Biodistribution of BPA and BSH after single, repeated and simultaneous administrations for neutron-capture therapy of cancer. Appl Radiat Isot; 2009 Jul;67(7-8 Suppl):S111-4
Hazardous Substances Data Bank. BORON, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In single intravenous (i.v.) administration, BSH (100 mg BSH/kg) showed no significant retention of (10)B in all the tissues, including tumors, while long-term retention of (10)B in the tumor, muscle and brain was observed with L-BPA (500 mg BPA/kg).
  • The dose escalation of L-BPA and the simultaneous single administration of L-BPA and BSH were not so effective at increasing boron accumulation in tumor after bolus i.v. injection.
  • The boron concentration in tumor was 41 microg B/g after single bolus i.v. injection even at the dose of 1000 mg BPA/kg.
  • In contrast, two sequential bolus i.v. injections of l-BPA with the dose of 500 mg BPA/kg each was found to be effective at increasing (10)B accumulation in the tumor; the maximum (10)B concentration in the tumor reached 52 microg B/g at 3 h after the second i.v. injection.
  • [MeSH-minor] Animals. Boron / pharmacokinetics. Cricetinae. Female. Isotopes / pharmacokinetics. Mesocricetus. Tissue Distribution

  • Hazardous Substances Data Bank. BORON COMPOUNDS .
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19376721.001).
  • [ISSN] 1872-9800
  • [Journal-full-title] Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine
  • [ISO-abbreviation] Appl Radiat Isot
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Borohydrides; 0 / Boron Compounds; 0 / Isotopes; 0 / Radiation-Sensitizing Agents; 0 / Sulfhydryl Compounds; 12294-22-3 / mercaptoundecahydrododecaborate; 47E5O17Y3R / Phenylalanine; N9E3X5056Q / Boron; UID84303EL / 4-boronophenylalanine
  •  go-up   go-down


26. Zhang S, Wang X, He Y, Ding R, Liu H, Xu J, Feng M, Li G, Wang M, Peng C, Qi C: (18)F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging. Bioorg Med Chem; 2010 Apr 1;18(7):2394-401
Hazardous Substances Data Bank. Bendamustine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F Labeled benzimidazole derivatives as potential radiotracer for positron emission tomography (PET) tumor imaging.
  • This article reported the synthesis and bioevaluation of two [(18)F] labeled benzimidazole derivatives, 4-(5-(2-[(18)F] fluoro-4-nitrobenzamido)-1-methyl-1H-benzimidazol-2-yl) butanoic acid ([(18)F] FNBMBBA, [(18)F]a1) and 3-(2-fluoroethyl)-7-methyl-2-propyl-3H-benzimidazole-5-carboxylic acid ([(18)F] FEMPBBA, [(18)F]b1) for PET tumor imaging.
  • Biodistribution assay in S180 tumor bearing mice of both compounds were carried out, and the results are both meaningful.
  • [(18)F] FEMPBBA which can be taken as a revision of [(18)F] FNBMBBA got an excellent result, and has significant advantages in some aspects compared with L-[(18)F] FET and [(18)F]-FDG in the same animal model, especially in tumor/brain uptake ratio.
  • The tumor/brain uptake ratio of [(18)F] FEMPBBA gets to 4.81, 7.15, and 9.8 at 30min, 60min and 120min, and is much higher than that of L-[(18)F] FET (2.54, 2.92 and 2.95) and [(18)F]-FDG (0.61, 1.02, 1.33) at the same time point.
  • The tumor/muscle and tumor/blood uptake ratio of [(18)F] FEMPBBA is also higher than that of L-[(18)F] FET at 30min and 60min.
  • This result indicates compound [(18)F] FEMPBBA is a promising radiotracer for PET tumor imaging.
  • [MeSH-major] Benzimidazoles / chemical synthesis. Fluorine Radioisotopes / chemistry. Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals / chemical synthesis
  • [MeSH-minor] Animals. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / chemistry. Bendamustine Hydrochloride. Chromatography, High Pressure Liquid. Female. Indicators and Reagents. Isotope Labeling. Mice. Nitrogen Mustard Compounds / chemical synthesis. Nitrogen Mustard Compounds / chemistry. Sarcoma 180 / radionuclide imaging. Solubility. Solvents. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20303769.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Fluorine Radioisotopes; 0 / Indicators and Reagents; 0 / Nitrogen Mustard Compounds; 0 / Radiopharmaceuticals; 0 / Solvents; 981Y8SX18M / Bendamustine Hydrochloride
  •  go-up   go-down


27. Carstanjen B, Schönert S, Heblinski N, Gruber AD: Primary unilateral fibroleiomyoma of the ovary in a pregnant mare: a case report. Reprod Domest Anim; 2009 Dec;44(6):952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This smooth muscle tumour may develop and increase in size during pregnancy.
  • Diagnosis is based on histological and immunohistochemical analyses.
  • Histologically, the ovarian fibroleiomyoma consists of non-invasive bundles of smooth muscle cells that synthesize collagen-like extracellular matrix.
  • [MeSH-major] Horse Diseases / pathology. Leiomyoma / veterinary. Ovarian Neoplasms / veterinary. Pregnancy Complications, Neoplastic / veterinary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18954381.001).
  • [ISSN] 1439-0531
  • [Journal-full-title] Reproduction in domestic animals = Zuchthygiene
  • [ISO-abbreviation] Reprod. Domest. Anim.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Kepenekci I, Demirkan A, Sözener U, Cakmak A, Demirer S, Alaçayir I, Ekinci C: Suprarenal symplastic leiomyoma of the inferior vena cava. Ann Vasc Surg; 2009 Nov-Dec;23(6):786.e11-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on a case of a leiomyoma in the inferior vena cava that appeared in the image to be located in the adrenal gland.
  • En bloc excision of the tumor with the right adrenal gland and the involved segment of the vena cava was carried out.
  • Histopathological work-up of the tumor revealed smooth muscle fibers and marked nuclear pleomorphism consistent with symplastic leiomyoma.
  • This case report presents a distinct histological variant of the rarely seen primary smooth muscle tumor of the inferior vena cava.
  • [MeSH-major] Leiomyoma. Vascular Neoplasms. Vena Cava, Inferior

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19733033.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Shan L, Hao Y, Wang S, Korotcov A, Zhang R, Wang T, Califano J, Gu X, Sridhar R, Bhujwalla ZM, Wang PC: Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate. Mol Imaging; 2008 Jan-Feb;7(1):42-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualizing head and neck tumors in vivo using near-infrared fluorescent transferrin conjugate.
  • Following intravenous administration of TfNIR (200 microL, 0.625 microg/microL), fluorescent signal was preferentially accumulated in JHU-013 tumor xenografts grown in the lower back (n=14) and oral base tissues (n=4) of nude mice.
  • The signal in tumors was clearly detectable as early as 10 minutes and reached the maximum at 90 to 120 minutes postinjection.
  • The background showed an increase, followed by a decrease at a much faster pace than tumor signal.
  • A high fluorescent ratio of the tumor to muscle was obtained (from 1.42 to 4.15 among tumors), usually achieved within 6 hours, and correlated with the tumor size (r=.74, p=.002).
  • [MeSH-major] Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / pathology. Infrared Rays. Transferrin / metabolism
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease Models, Animal. Endocytosis. Exocytosis. Fluorescence. Humans. Mice. Neoplasm Transplantation. Receptors, Transferrin / metabolism. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18384723.001).
  • [ISSN] 1535-3508
  • [Journal-full-title] Molecular imaging
  • [ISO-abbreviation] Mol Imaging
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 2G12 RR003048; United States / NCI NIH HHS / CA / 5P20 CA118770; United States / NCI NIH HHS / CA / 5U 54CA091431
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Transferrin; 0 / Transferrin
  •  go-up   go-down


30. Tanaka YO, Tsunoda H, Sugano M, Satoh T, Yagi H, Minami R, Shiigai M, Inadome Y, Yoshikawa H, Noguchi M, Minami M: MR and CT findings of leiomyomatosis peritonealis disseminata with emphasis on assisted reproductive technology as a risk factor. Br J Radiol; 2009 Mar;82(975):e44-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyomatosis peritonealis disseminata (LPD) is a rare benign smooth muscle tumour located in the peritoneal cavity.
  • [MeSH-major] Estrogens / physiology. Leiomyomatosis / diagnosis. Peritoneal Neoplasms / diagnosis. Pregnancy Complications, Neoplastic / diagnosis. Reproductive Techniques, Assisted / adverse effects

  • MedlinePlus Health Information. consumer health - Assisted Reproductive Technology.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211902.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Estrogens
  •  go-up   go-down


31. Schwartz PE, Kelly MG: Malignant transformation of myomas: myth or reality? Obstet Gynecol Clin North Am; 2006 Mar;33(1):183-98, xii
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The possibility that a fibroid may actually be a smooth muscle tumor of uncertain malignant potential or a leiomyosarcoma often dictates the clinical management of rapidly growing fibroids.
  • The clinician must be aware that the infrequent occurrence of uterine leiomyosarcomas makes it difficult to establish absolutely firm recommendations for the diagnosis and management of this disease, particularly with regard to fertility preservation.
  • Nevertheless, this article addresses major issues that a clinician might face in the evaluation of a smooth muscle tumor of the uterus that clinically may be malignant.
  • [MeSH-major] Leiomyoma / pathology. Leiomyosarcoma / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504815.001).
  • [ISSN] 0889-8545
  • [Journal-full-title] Obstetrics and gynecology clinics of North America
  • [ISO-abbreviation] Obstet. Gynecol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Wei CH, Qian J, Bi YW, Chen RJ, Yao YQ, Yuan YF: [Orbital solitary fibrous tumor: a clinicopathologic analysis]. Zhonghua Yan Ke Za Zhi; 2008 Aug;44(8):691-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital solitary fibrous tumor: a clinicopathologic analysis].
  • OBJECTIVE: To study clinicopathologic features, histologic characteristics, differential diagnosis and the treatment of orbital solitary fibrous tumor (SFT).
  • The location of the tumor was in the muscle cone (case 1 and case 5), medial (case 3), lateral (case 4), superior (case 2) and inferolateral (case 6) portion of the orbit, respectively.
  • Histologically, SFT displayed as a mass of spindle cells in an irregular arrangement Sometime, tumor cells could be storiform or sarciniform.
  • CONCLUSIONS: SFT is a rare orbital tumor and could be confused with other types of orbital tumors.
  • This tumor can be diagnosed by pathological and immunocytochemical studies, these characteristics can be used to differentiate it from other types of orbital tumors.
  • [MeSH-major] Fibroma / diagnosis. Fibroma / pathology. Orbital Neoplasms / diagnosis. Orbital Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115630.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


33. Ohira T, Okuma T, Matsuoka T, Wada Y, Nakamura K, Watanabe Y, Inoue Y: FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits. Cardiovasc Intervent Radiol; 2009 Jan;32(1):114-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-MicroPET and diffusion-weighted MR image evaluation of early changes after radiofrequency ablation in implanted VX2 tumors in rabbits.
  • The objective of this study was to evaluate the early changes after radiofrequency ablation (RFA) in VX2 rabbit tumors implanted into the back muscles by diffusion-weighted magnetic resonance (MR) imaging and (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography ((18)F-FDG PET).
  • Percutaneous CT-guided RFA was conducted in seven rabbits with implanted VX2 tumors.
  • VX2 tumors on the other side were untreated and served as the control.
  • The mean apparent diffusion coefficient (ADC) values and radioactivity count of untreated and ablated tumors were calculated.
  • Untreated VX2 tumors showed hyperintensity on T1-, T2-, and diffusion-weighted MR images, ring-enhanced on contrast-enhanced T1-weighted imaging, and ring-shaped FDG accumulation on FDG-PET.
  • Ablated VX2 tumors showed slight hyperintensity on T1-, T2-, and diffusion-weighed images, slight enhancement on contrast-enhanced T1-weighted images, and low accumulation on FDG-PET.
  • The ADC value of ablated VX2 tumors (1.52 +/- 0.24 x 10(-3) mm(2)/s) was significantly higher than that of untreated tumors (1.09 +/- 0.12 x 10(-3); p < 0.05).
  • The tumor/muscle ratio of ablated tumors (0.5 +/- 0.3) was significantly lower than that of untreated tumors (11.6 +/- 3.2; p < 0.05).
  • Histopathological examination confirmed the lack of viable tumor cells in the ablated lesions.
  • The results indicate that both ADC value and FDG-PET are potentially useful markers for monitoring the early effects of RFA.
  • [MeSH-major] Catheter Ablation. Diffusion Magnetic Resonance Imaging / methods. Muscle Neoplasms / surgery. Positron-Emission Tomography / methods
  • [MeSH-minor] Animals. Contrast Media. Disease Models, Animal. Fluorodeoxyglucose F18. Neoplasm Transplantation. Rabbits. Radiography, Interventional. Radiopharmaceuticals. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696151.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Dionne JM, Carter JE, Matsell D, MacNeily AE, Morrison KB, de Sa D: Renal leiomyoma associated with Epstein-Barr virus in a pediatric transplant patient. Am J Kidney Dis; 2005 Aug;46(2):351-5
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal leiomyoma is a rare smooth muscle tumor of the kidney.
  • An association between Epstein-Barr virus and smooth muscle tumors in immunocompromised patients recently has been recognized.
  • Possible factors involved in the tumor pathogenesis in our patient are discussed, including immunosuppression, growth hormone therapy, and Epstein-Barr virus induction.
  • [MeSH-major] Epstein-Barr Virus Infections / transmission. Kidney Neoplasms / virology. Kidney Transplantation / adverse effects. Leiomyoma / virology. Postoperative Complications / virology. Transplantation, Homologous / adverse effects
  • [MeSH-minor] Child, Preschool. Disease Transmission, Infectious. Female. Growth Disorders / etiology. Humans. Hydronephrosis / complications. Kidney / abnormalities. Kidney / chemistry. Kidney / pathology. Kidney / virology. Kidney Failure, Chronic / etiology. Kidney Failure, Chronic / surgery. Kidney Function Tests. Male. Middle Aged. Nephrectomy. Nephritis, Interstitial / etiology. RNA, Viral / analysis. Recurrence. Renal Dialysis. Urethra / abnormalities. Urinary Tract Infections / etiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112056.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Viral
  • [Number-of-references] 26
  •  go-up   go-down


35. Lee CH, Jan YJ, Chen JT, Ho WL, Tseng CH, Wang J: Colorectal mesenchymal tumor: a clinicopathologic study of 25 cases. J Chin Med Assoc; 2005 Jul;68(7):291-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal mesenchymal tumor: a clinicopathologic study of 25 cases.
  • BACKGROUND: It is important to distinguish gastrointestinal stromal tumors (GISTs) from other gastrointestinal mesenchymal tumors (GIMTs), because of the malignant potential of GISTs and the availability of molecular targeted therapy.
  • The first objective of our retrospective study was to reclassify colorectal mesenchymal tumors, from files collected over 20 years, to determine if, based on immunohistologic features, the lesions were truly GISTs.
  • METHODS: We evaluated all cases of colorectal mesenchymal tumor identified from the database of the Department of Surgical Pathology at Taichung Veterans General Hospital for the period 1983-2001.
  • For 25 patients, clinical data, and information about tumor characteristics, surgical procedures, and survival outcomes, were obtained and analyzed.
  • RESULTS: The following variables were significantly associated with different CD117 results: symptomatic presentation, location, gross features, tumor size, mitotic count, cellularity, and type of surgery.
  • Only 18 tumors were identified as GISTs.
  • For these, the following variables were significantly associated (by univariate analysis) with increased lethality: tumor size (p = 0.049); mitotic count (p = 0.019); nuclear atypia (p = 0.019); and tumor necrosis (p = 0.045).
  • CONCLUSION: Two clinicopathologically different categories were identified from our colorectal mesenchymal tumors: intramural GISTs and polypoid submucosal leiomyomas.
  • Our study suggests that GIST is a better categorization than smooth muscle tumor because of the malignant potential.
  • However, tumor size, nuclear atypia and tumor necrosis are probably also significant predictive factors of lethality.
  • [MeSH-major] Colorectal Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038368.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


36. Gibbs KE, White A, Kaleya R: Laparoscopic management of an adrenal leiomyoma in an AIDS patient. A case report and review of the literature. JSLS; 2005 Jul-Sep;9(3):345-8
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a case of an enlarging smooth muscle tumor of the adrenal gland in an acquired immunodeficiency syndrome (AIDS) patient and review the sparse literature available on this subject.
  • DISCUSSION: Benign, smooth muscle tumors arising from the adrenal glands are rare.
  • A review of the literature does reveal a propensity for these tumors to occur in the immunocompromised population.
  • CONCLUSION: The ability to manage these tumors laparoscopically is of significant benefit to patients.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1998 Oct;69(2):111-2 [9808515.001]
  • [Cites] World J Surg. 2000 May;24(5):579-82 [10787080.001]
  • [Cites] World J Surg. 2001 Jul;25(7):905-13 [11572032.001]
  • [Cites] Pediatr Hematol Oncol. 1991 Jul-Sep;8(3):235-41 [1742182.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):545-6 [1503021.001]
  • [Cites] Ann Surg. 1997 May;225(5):495-501; discussion 501-2 [9193177.001]
  • [Cites] Abdom Imaging. 1994 May-Jun;19(3):259-61 [8019358.001]
  • [Cites] Clin Imaging. 1994 Oct-Dec;18(4):277-8 [8000956.001]
  • [Cites] Pediatr Pathol Lab Med. 1995 Nov-Dec;15(6):923-9 [8705202.001]
  • [Cites] AIDS. 1996 Mar;10(3):340-1 [8882677.001]
  • [Cites] Surg Endosc. 1994 Feb;8(2):135-8 [8165486.001]
  • (PMID = 16121885.001).
  • [ISSN] 1086-8089
  • [Journal-full-title] JSLS : Journal of the Society of Laparoendoscopic Surgeons
  • [ISO-abbreviation] JSLS
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 12
  • [Other-IDs] NLM/ PMC3015615
  •  go-up   go-down


37. Mahy P, De Bast M, Gillart J, Labar D, Grégoire V: Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis. Eur J Nucl Med Mol Imaging; 2006 May;33(5):553-6
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
  • In the framework of the preclinical validation of the hypoxic tracer [(18)F]EF3, a comparison was performed between uptake of [(18)F]EF3 and EF5 adducts detected by immunofluorescence in MCa-4, FSA, FSAII, Sa-NH and NFSA tumour-bearing mice.
  • A significant correlation (r (2)=0.57; p<0.01) was found between the [(18)F]EF3 tumour-to-muscle ratio and the fluorescence intensity of EF5.
  • [MeSH-major] Etanidazole / analogs & derivatives. Fibrosarcoma / metabolism. Fibrosarcoma / radionuclide imaging. Hydrocarbons, Fluorinated / metabolism. Mammary Neoplasms, Experimental / metabolism. Mammary Neoplasms, Experimental / radionuclide imaging. Nitroimidazoles / pharmacokinetics. Oxygen / metabolism
  • [MeSH-minor] Animals. Cell Hypoxia. Drug Evaluation, Preclinical. Fluorescent Antibody Technique. Male. Metabolic Clearance Rate. Mice. Mice, Inbred C3H. Organ Specificity. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16523307.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide; 0 / 2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide; 0 / Hydrocarbons, Fluorinated; 0 / Nitroimidazoles; 0 / Radiopharmaceuticals; 30DKA3Q1HL / Etanidazole; S88TT14065 / Oxygen
  •  go-up   go-down


38. Dreux AC, Lamb DJ, Modjtahedi H, Ferns GA: The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis; 2006 May;186(1):38-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EGF receptor mediated processes have been well characterised within epithelial, smooth muscle and tumour cell lines in vitro, and the EGF receptor has been identified immunocytochemically on intimal smooth muscle cells within atherosclerotic plaques.


39. Heng HG, Huang A, Baird DK, Mitsui I, Parnell NK: Imaging diagnosis--spontaneous intramural canine duodenal hematoma. Vet Radiol Ultrasound; 2010 Mar-Apr;51(2):178-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging diagnosis--spontaneous intramural canine duodenal hematoma.
  • A presumptive diagnosis of pancreatitis and smooth muscle tumor of the duodenum leading to common bile duct obstruction was made.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20402407.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Tielliu IF, Otterman ML, Meuzelaar JJ, Zeebregts CJ, Peeters PM: Intravenous leiomyomatosis: report of two cases and strategy for surgical resection. Minerva Chir; 2010 Aug;65(4):489-93
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravenous leiomyomatosis is a rare smooth muscle tumour that arises from the myometrium and grows into the extrauterine venous system.
  • On the basis of two cases of intravenous leiomyomatosis with different levels of intracaval extension of the tumour, this article discusses a useful strategy for planning surgical resection, taking into account tumour characteristics and different levels of intracaval extension.
  • [MeSH-major] Heart Neoplasms / surgery. Leiomyomatosis / surgery. Uterine Neoplasms / surgery. Vascular Neoplasms / surgery. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Cardiac Surgical Procedures / methods. Female. Heart Atria / surgery. Humans. Middle Aged. Neoplasm Invasiveness. Treatment Outcome. Vascular Surgical Procedures / methods

  • Genetic Alliance. consumer health - Intravenous leiomyomatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20802437.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


41. Giglio J, Patsis G, Pirmettis I, Papadopoulos M, Raptopoulou C, Pelecanou M, León E, González M, Cerecetto H, Rey A: Preparation and characterization of technetium and rhenium tricarbonyl complexes bearing the 4-nitrobenzyl moiety as potential bioreductive diagnostic radiopharmaceuticals. In vitro and in vivo studies. Eur J Med Chem; 2008 Apr;43(4):741-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synthesis of a ligand containing a nitrobenzyl group as bioreductive pharmacophore and the preparation of the corresponding technetium and rhenium complexes are presented. (99m)Tc labelling was performed in high yield (>90%) by ligand substitution using fac-[(99m)Tc(CO)(3)(H(2)O)(3)](+) as precursor.
  • Biodistribution in normal mice was characterized by fast blood and soft tissue depuration and combined excretion via the hepatobiliary and urinary systems.
  • Tumour uptake was low, probably due to low lipophilicity but tumour/muscle ratios were favourable as a consequence of high excretion.
  • [MeSH-minor] Animals. Cell Hypoxia. Crystallography, X-Ray. Diagnostic Imaging. In Vitro Techniques. Liver / metabolism. Lung / metabolism. Mice. Models, Molecular. Molecular Structure. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / etiology. Sarcoma, Experimental / metabolism. Spectrophotometry, Infrared. Structure-Activity Relationship. Tissue Distribution. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17658668.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 7440-15-5 / Rhenium
  •  go-up   go-down


42. Zhang T, Zhou NK, Zhang JM, Liang CY, Liu X, Tian XD: [Comparison of the biodistribution and PET imaging with (11)C-PDT and (18)F-FDG in the mouse model of lung adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Feb;32(2):103-6
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The objective of this study was to compare the biodistribution and PET imaging of (11)C-PDT and (18)F-FDG in a mouse model of lung adenocarcinoma, and to evaluate the value of (11)C-PDT as a new tracer for PET imaging of lung cancer.
  • RESULTS: Considerable uptake of the both radioactive tracers in the tumors was observed.
  • The tumor uptake of (11)C-PDT [(0.65 +/- 0.20)%ID/g] was significantly lower than that of (18)F-FDG [(7.44 +/- 1.56)%ID/g, P < 0.01].
  • In the (11)C-PDT group, the highest uptake was observed in the liver, kidney and blood in a successively declining order, while the highest uptake of (18)F-FDG was seen in a order of heart, tumor and kidneys.
  • The tumor/muscle ratio of (11)C-PDT uptake was relatively high (2.02 +/- 0.56), but still lower than that of (18)F-FDG (2.95 +/- 0.49, P < 0.01).
  • All values of other tumor/organ ratios (T/NT) of (11)C-PDT uptake were < 2.
  • High radioactive uptake was showed in the tumor and abdominal organs on PET images in the tumor-bearing mice injected with (11)C-PDT, and (18)F-FDG uptake was showed in the heart, tumor and abdominal organs.
  • The tumor PET images with (11)C-PDT and (18)F-FDG were all clear.
  • CONCLUSION: The uptake of (11)C-PDT in lung cancer is higher than that in muscle tissues, and pulmonary cancers can be detected by PET imaging. (11)C-PDT may be a promising PET tracer for lung cancers.
  • [MeSH-major] Adenocarcinoma / metabolism. Carbon Radioisotopes / pharmacokinetics. Fluorodeoxyglucose F18 / pharmacokinetics. Lung Neoplasms / metabolism. Podophyllotoxin / pharmacokinetics
  • [MeSH-minor] Animals. Cell Line, Tumor. Kidney / metabolism. Kidney / radionuclide imaging. Liver / metabolism. Liver / radionuclide imaging. Mice. Myocardium / metabolism. Positron-Emission Tomography. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20403239.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


43. Ptacek T, Song C, Walker CL, Sell SM: Physical mapping of distinct 7q22 deletions in uterine leiomyoma and analysis of a recently annotated 7q22 candidate gene. Cancer Genet Cytogenet; 2007 Apr 15;174(2):116-20
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Physical mapping of distinct 7q22 deletions in uterine leiomyoma and analysis of a recently annotated 7q22 candidate gene.
  • Uterine leiomyoma (UL) is a benign, smooth muscle tumor of the uterus affecting a significant proportion of women of reproductive age.
  • Members of this family are transmembrane proteins with roles in differentiation, proliferation, and extracellular matrix formation, and have been implicated in other tumors.
  • [MeSH-major] Chromosome Deletion. Chromosomes, Human, Pair 7 / genetics. Genetic Predisposition to Disease. Leiomyoma / genetics. Physical Chromosome Mapping / methods. Uterine Neoplasms / genetics

  • Genetic Alliance. consumer health - Uterine Fibroid.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17452252.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R25CA076023-07; United States / NIDDK NIH HHS / DK / P30DK056336
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myelin Proteins; 0 / PMP22 protein, human
  •  go-up   go-down


44. Rammeh-Rommani S, Mokni M, Stita W, Trabelsi A, Hamissa S, Sriha B, Tahar-Yacoubi M, Korbi S: [Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases]. J Gynecol Obstet Biol Reprod (Paris); 2005 Oct;34(6):568-71
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Uterine smooth muscle tumors: retrospective epidemiological and pathological study of 2760 cases].
  • [Transliterated title] Les tumeurs musculaires lisses de l'utérus: étude épidémiologique et anatomo-pathologique rétrospective de 2760 cas.
  • INTRODUCTION: Smooth muscle tumors of the uterus are frequent.
  • Some leiomyomas may have unusual morphologic features difficult to distinguish from leiomyosarcoma.
  • These tumors are: cellular leiomyoma, atypical leiomyoma and mitotically active leiomyoma.
  • OBJECTIVES: The purpose of our work is to study cases of leiomyosarcomas, cellular leiomyoma, atypical leiomyoma and mitotically active leiomyoma among a large series of uterine smooth muscle tumors.
  • MATERIALS AND METHODS: We reviewed retrospectively 2760 uterine smooth muscle tumors.
  • The slides were reviewed and the tumors reclassified according to the criteria of the WHO 2003 classification.
  • RESULTS: Review of the slides demonstrated: 12 mitotically active leiomyomas, 18 cellular leiomyomas, 20 atypical leiomyomas, 16 leiomysarcomas, only one case of smooth muscle tumor of uncertain malignant potential.
  • The 2709 remaining tumors were all common leiomyomas.
  • [MeSH-major] Uterine Neoplasms / epidemiology. Uterine Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Leiomyoma / epidemiology. Leiomyoma / pathology. Neoplasm Recurrence, Local. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208199.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


45. Heller LC, Ugen K, Heller R: Electroporation for targeted gene transfer. Expert Opin Drug Deliv; 2005 Mar;2(2):255-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo electroporation, which has previously been used clinically to deliver chemotherapeutic agents, also enhances the delivery of plasmid DNA and has been used to deliver plasmids to several tissue types, particularly muscle and tumour.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16296752.001).
  • [ISSN] 1742-5247
  • [Journal-full-title] Expert opinion on drug delivery
  • [ISO-abbreviation] Expert Opin Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Growth Substances; 0 / Toxins, Biological; 0 / Vaccines, DNA; 11096-26-7 / Erythropoietin; 187348-17-0 / Interleukin-12
  • [Number-of-references] 129
  •  go-up   go-down


46. Giglio J, Rey A, Cerecetto H, Pirmettis I, Papadopoulos M, León E, Monge A, López de Ceráin A, Azqueta A, González M, Fernández M, Paolino A, León A: Design and evaluation of "3 + 1" mixed ligand oxorhenium and oxotechnetium complexes bearing a nitroaromatic group with potential application in nuclear medicine oncology. Eur J Med Chem; 2006 Oct;41(10):1144-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The synthesis and evaluation of a series of oxotechnetium and oxorhenium complexes containing a nitroaromatic moiety as potential radiopharmaceuticals for targeting tumour hypoxia is presented.
  • Biodistribution in normal animals was characterized by high initial blood, lung and liver uptake, fast blood and soft tissue depuration and preferential excretion via the hepatobiliary system.
  • Initial tumour uptake was moderate but tumour/muscle ratios for complexes III and IV, were favourable at all time points.
  • Although the results are encouraging further development is still necessary in order to achieve higher tumour uptake and lower gastrointestinal activity.
  • [MeSH-minor] Animals. Anoxia. Cell Line. Cell Proliferation / drug effects. China. Cricetinae. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Design. Drug Screening Assays, Antitumor. Female. Gamma Cameras. Ligands. Mice. Molecular Structure. Neoplasms, Experimental. Sensitivity and Specificity. Structure-Activity Relationship. Tissue Distribution / drug effects. Xenograft Model Antitumor Assays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16782237.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Ligands; 0 / Nitrobenzenes; 0 / Organometallic Compounds; 0 / Organotechnetium Compounds; 14333-24-5 / perrhenate; 7440-15-5 / Rhenium
  •  go-up   go-down


47. Berretta R, Rolla M, Merisio C, Giordano G, Nardelli GB: Uterine smooth muscle tumor of uncertain malignant potential: a three-case report. Int J Gynecol Cancer; 2008 Sep-Oct;18(5):1121-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumor of uncertain malignant potential: a three-case report.
  • Based on the degree of cytologic atypia, mitotic activity, and other features, uterine smooth muscle tumors have historically been grouped into two classes: benign leiomyomas and malignant leiomyosarcomas.
  • However, this separation holds true more in principle than in practice because the tumor's biological potential may not always be determined with certainty, complicating diagnosis, and therapy.
  • We report three cases of patients with uterine smooth muscle tumors of uncertain malignant potential.
  • Uterine smooth muscle tumors of uncertain malignant potential may have an unpredictable clinical course and may metastasize to seemingly low-grade neoplasms in distant sites even after several years and even in the absence of important negative prognostic predictors, such as coagulative tumor cell necrosis.
  • [MeSH-major] Smooth Muscle Tumor / pathology. Uncertainty. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans. Lung Neoplasms / secondary. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986240.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Gupta A, Chandra N, Sharma A, Husain N, Kureel SN: Renal leiomyoma in a child: a rare renal tumor. J Pediatr Surg; 2010 Sep;45(9):1900-3
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal leiomyoma in a child: a rare renal tumor.
  • Renal leiomyoma is a rare benign smooth muscle tumor of the kidney.
  • We report a case of right renal leiomyoma in a 6-year-old boy which was suspected of being a Wilms tumor.
  • Contrast-enhanced computed tomography could not differentiate leiomyoma in the kidney, and the mass was diagnosed as a Wilms tumor.
  • Diagnosis of renal leiomyoma could only be achieved after histopathologic examination and immunohistochemistry.
  • We recommend that total nephrectomy has to be done in most cases of pediatric renal tumors to avoid the risk of malignancy.
  • There may be a role for nephron sparing surgery, provided the tumor is small, and one has a strong suspicion for the lesion being benign.
  • [MeSH-major] Kidney Neoplasms / surgery. Leiomyoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20850642.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Wyss MT, Honer M, Schubiger PA, Ametamey SM: NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours. Eur J Nucl Med Mol Imaging; 2006 Mar;33(3):311-8
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NanoPET imaging of [(18)F]fluoromisonidazole uptake in experimental mouse tumours.
  • PURPOSE: The purpose of this study was to assess the potential and utility of ultra-high-resolution hypoxia imaging in various murine tumour models using the established hypoxia PET tracer [(18)F]fluoromisonidazole ([(18)F]FMISO).
  • METHODS: [(18)F]FMISO PET imaging was performed with the dedicated small-animal PET scanner NanoPET (Oxford Positron Systems) and ten different human tumour xenografts in nude mice as well as B16 melanoma tumours in syngeneic Balb/c mice.
  • For comparison, [(18)F]fluorodeoxyglucose ([(18)F]FDG) PET scans were also performed in the mice bearing human tumour xenografts.
  • RESULTS: In 10 out of 11 experimental tumour models, [(18)F]FMISO PET imaging allowed clear-cut visualisation of the tumours.
  • In addition to average TMRR (tumour-to-muscle retention ratio including all voxels in a volume of interest (VOI)), the parameters TMRR(75%) and TMRR(5) (tumour-to-muscle retention ratio including voxels of 75% or more of the maximum radioactivity in a VOI and the five hottest pixels, respectively) also served as measures for quantifying the heterogeneous [(18)F]FMISO uptake in the tumours.
  • The variability observed in [(18)F]FMISO uptake was related neither to tumour size nor to the injected mass of the radiotracer.
  • The pattern of normoxic and hypoxic regions within the human tumour xenografts, however, correlated with glucose metabolism as revealed by comparison of [(18)F]FDG and [(18)F]FMISO images.
  • CONCLUSION: This study demonstrates the feasibility and utility of [(18)F]FMISO for imaging murine tumour models using NanoPET.
  • [MeSH-major] Misonidazole / analogs & derivatives. Nanotechnology / instrumentation. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / radionuclide imaging. Oxygen / metabolism. Positron-Emission Tomography / instrumentation
  • [MeSH-minor] Animals. Cell Hypoxia. Equipment Design. Equipment Failure Analysis. Feasibility Studies. Female. Metabolic Clearance Rate. Mice. Mice, Inbred BALB C. Mice, Nude. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258762.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 13551-89-8 / fluoromisonidazole; 8FE7LTN8XE / Misonidazole; S88TT14065 / Oxygen
  •  go-up   go-down


50. Pisano R, Breda M, Grassi S, James CA: Hydrophilic interaction liquid chromatography-APCI-mass spectrometry determination of 5-fluorouracil in plasma and tissues. J Pharm Biomed Anal; 2005 Jul 15;38(4):738-45
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After addition of internal standard (IS) (5-Chlorouracil (5-CU)), plasma proteins were precipitated with acetonitrile, and tissue samples homogenised with a micro-dismembrator.
  • The lower limits of quantitation in plasma and tissues were about 5 ng/ml and 10 ng/g, respectively, using 25 microl of plasma and 50mg of tissue.
  • The suitability and robustness of the method for in vivo samples were confirmed by analysis of mouse plasma, muscle and tumour from animals dosed with 5-FU.
  • [MeSH-minor] Animals. Calibration. Chemistry, Physical. Chromatography, Liquid. Mass Spectrometry. Mice. Physicochemical Phenomena. Reference Standards. Tissue Distribution. Uracil / analogs & derivatives. Uracil / analysis. Uracil / blood. Uracil / pharmacokinetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967302.001).
  • [ISSN] 0731-7085
  • [Journal-full-title] Journal of pharmaceutical and biomedical analysis
  • [ISO-abbreviation] J Pharm Biomed Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites; 56HH86ZVCT / Uracil; 7LQ4V03RNY / 5-chlorouracil; U3P01618RT / Fluorouracil
  •  go-up   go-down


51. Crossland H, Constantin-Teodosiu D, Greenhaff PL, Gardiner SM: Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle. J Physiol; 2010 Apr 15;588(Pt 8):1333-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose dexamethasone prevents endotoxaemia-induced muscle protein loss and impairment of carbohydrate oxidation in rat skeletal muscle.
  • We recently provided evidence suggesting a role for cytokine-mediated inhibition of Akt/Forkhead box O 1 (FOXO1) signalling in the induction of muscle atrophy and impairment of muscle carbohydrate oxidation during lipopolysaccharide (LPS)-induced endotoxaemia in rats.
  • We hypothesized that a low-dose dexamethasone (Dex; anti-inflammatory agent) infusion during endotoxaemia would prevent the LPS-induced impairment of Akt/FOXO1 signalling, and therefore prevent the muscle atrophy and impairment of carbohydrate oxidation.
  • LPS infusion caused haemodynamic changes consistent with a hyperdynamic circulation and induced increases in muscle tumour necrosis factor-alpha (TNF-alpha; 10-fold, P < 0.001), interleukin-6 (IL-6; 14-fold, P < 0.001) and metallothionein-1A (MT-1A; 187-fold, P < 0.001) mRNA expression.
  • Dex co-administration abolished most of the haemodynamic effects of LPS and reduced the increase in muscle TNF-alpha, IL-6 and MT-1A by 51% (P < 0.01), 85% (P < 0.001) and 58% (P < 0.01), respectively.
  • Dex infusion during endotoxaemia also prevented the LPS-induced 40% reduction in the muscle protein:DNA ratio and decrease in Akt phosphorylation, and partially prevented the reduction in FOXO1 phosphorylation.
  • However, Dex did not prevent the LPS-mediated increase in muscle atrophy F-box (MAFbx) and muscle RING finger 1 (MuRF1) mRNA expression, but did significantly reduce the LPS-mediated increase in cathepsin-L mRNA expression and enzyme activity by 43% (P < 0.001) and 53% (P < 0.05), respectively.
  • Furthermore, Dex suppressed LPS-induced pyruvate dehydrogenase kinase 4 (PDK4) mRNA upregulation by approximately 50% (P < 0.01), and prevented LPS-mediated muscle glycogen breakdown and lactate accumulation.
  • Thus, low-dose Dex infusion during endotoxaemia prevented muscle atrophy and the impairment of carbohydrate oxidation, potentially through suppression of cytokine-mediated Akt/FOXO inhibition, and blunting of cathepsin-L-mediated lysosomal protein breakdown.

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Autophagy. 2008 Apr;4(3):378-80 [18227643.001]
  • [Cites] J Physiol. 2007 Aug 15;583(Pt 1):381-90 [17540700.001]
  • [Cites] J Physiol. 2008 Mar 15;586(6):1767-75 [18218678.001]
  • [Cites] Autophagy. 2008 May;4(4):524-6 [18367868.001]
  • [Cites] Arch Biochem Biophys. 2008 Jun 1;474(1):91-101 [18328801.001]
  • [Cites] J Steroid Biochem Mol Biol. 2008 May;110(1-2):125-9 [18436443.001]
  • [Cites] Br J Pharmacol. 2008 Aug;154(8):1600-10 [18500354.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2008 Oct;295(4):H1753-62 [18757479.001]
  • [Cites] Am J Physiol Cell Physiol. 2008 Oct;295(4):C986-93 [18701653.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Oct;295(4):E762-71 [18492780.001]
  • [Cites] J Physiol. 2008 Nov 15;586(Pt 22):5589-600 [18818241.001]
  • [Cites] J Physiol. 2009 Jan 15;587(Pt 1):219-30 [19001041.001]
  • [Cites] J Physiol. 2009 Jan 15;587(Pt 1):231-9 [19001043.001]
  • [Cites] J Physiol. 2009 Feb 15;587(Pt 4):713-9 [19218620.001]
  • [Cites] Biochem J. 2010 Apr 1;427(1):171-8 [20088826.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):47-55 [18035477.001]
  • [Cites] Toxicology. 2000 Nov 30;155(1-3):17-26 [11154793.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7):1303-10 [11445675.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7 Suppl):S117-20 [11445745.001]
  • [Cites] Biochem J. 2001 Nov 15;360(Pt 1):143-50 [11696001.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1704-8 [11679633.001]
  • [Cites] Br J Anaesth. 2003 Feb;90(2):221-32 [12538380.001]
  • [Cites] Int Immunopharmacol. 2003 Apr;3(4):571-9 [12689661.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):365-71 [12820900.001]
  • [Cites] FASEB J. 2004 Jan;18(1):39-51 [14718385.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2004 May;7(3):265-9 [15075917.001]
  • [Cites] Mol Cell. 2004 May 7;14(3):395-403 [15125842.001]
  • [Cites] Diabetes. 2004 Jul;53(7):1790-7 [15220203.001]
  • [Cites] Cell. 2004 Oct 15;119(2):285-98 [15479644.001]
  • [Cites] Scand J Clin Lab Invest. 1974 Apr;33(2):109-20 [4852173.001]
  • [Cites] Comput Biol Med. 1987;17(2):85-99 [3581810.001]
  • [Cites] N Engl J Med. 1987 Sep 10;317(11):653-8 [3306374.001]
  • [Cites] Circ Shock. 1989 May;28(1):59-68 [2731322.001]
  • [Cites] Metabolism. 1990 Oct;39(10):1096-107 [2215256.001]
  • [Cites] Am J Physiol. 1991 Mar;260(3 Pt 1):E430-5 [1900669.001]
  • [Cites] Clin Sci (Lond). 1991 Aug;81(2):249-56 [1716189.001]
  • [Cites] Am J Physiol. 1992 Apr;262(4 Pt 1):E427-33 [1566829.001]
  • [Cites] Mol Cell Biochem. 1993 Aug 11;125(1):11-8 [8264567.001]
  • [Cites] J Biol Chem. 1995 Jan 27;270(4):1850-8 [7829521.001]
  • [Cites] Clin Investig. 1994 Oct;72(10):782-7 [7865982.001]
  • [Cites] Crit Care Med. 1995 Aug;23(8):1430-9 [7634816.001]
  • [Cites] Clin Sci (Lond). 1995 Oct;89(4):431-9 [7493444.001]
  • [Cites] J Clin Invest. 1996 Jan 15;97(2):339-48 [8567953.001]
  • [Cites] J Clin Invest. 1996 Apr 1;97(7):1610-7 [8601625.001]
  • [Cites] Crit Care Med. 1996 Apr;24(4):575-83 [8612406.001]
  • [Cites] Br J Pharmacol. 1996 May;118(1):141-9 [8733587.001]
  • [Cites] Am J Physiol. 1997 Mar;272(3 Pt 2):R849-56 [9087646.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):197-203 [9202072.001]
  • [Cites] Shock. 1998 Oct;10(4):298-306 [9788663.001]
  • [Cites] Br J Pharmacol. 1998 Dec;125(7):1543-50 [9884083.001]
  • [Cites] J Nutr. 1999 Jan;129(1S Suppl):227S-237S [9915905.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):202-4, 206 [10023525.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Crit Care Med. 2004 Nov;32(11 Suppl):S527-33 [15542960.001]
  • [Cites] J Appl Physiol (1985). 2005 Mar;98(3):911-7 [15542570.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Oct;37(10):2156-68 [16125115.001]
  • [Cites] Diabetes. 2005 Oct;54(10):2939-45 [16186396.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1711-23 [16236742.001]
  • [Cites] Diabetes. 2006 Aug;55(8):2311-7 [16873695.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4160-8 [16777975.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Feb;292(2):E501-12 [17003238.001]
  • [CommentIn] J Physiol. 2010 Apr 15;588(Pt 8):1193 [20395471.001]
  • (PMID = 20176631.001).
  • [ISSN] 1469-7793
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Glucocorticoids; 0 / Interleukin-6; 0 / Lipopolysaccharides; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / Tumor Necrosis Factor-alpha; 147604-79-3 / Foxo1 protein, rat; 7S5I7G3JQL / Dexamethasone; EC 2.7.- / Protein Kinases; EC 2.7.1.- / pyruvate dehydrogenase kinase 4; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2872737
  •  go-up   go-down


52. Ramaprasad S, Ripp E, Missert J, Pandey RK: In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model. Curr Drug Discov Technol; 2007 Aug;4(2):126-32
Hazardous Substances Data Bank. FLUORINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo 19F MR studies of fluorine labeled photosensitizers in a murine tumor model.
  • This process is studied by (19)F in vivo MR methodology in a murine tumor model.
  • The animal model used in these studies was mice bearing radiation induced fibrosarcoma (RIF) tumor on the foot dorsum.
  • The mice were injected with a solution of approximately 100 micro-moles of the fluorinated photosensitizer and the (19)F MR examination of the photosensitizer in the tumor or the muscle was performed.
  • [MeSH-major] Fibrosarcoma / metabolism. Neoplasms, Experimental / metabolism. Photosensitizing Agents / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Fluorine. Magnetic Resonance Imaging. Mice

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17691914.001).
  • [ISSN] 1570-1638
  • [Journal-full-title] Current drug discovery technologies
  • [ISO-abbreviation] Curr Drug Discov Technol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 284SYP0193 / Fluorine
  •  go-up   go-down


53. Kristek J, Marjanović K, Dmitrović B, Krajinović Z, Sakić K: Trichinella spiralis and breast carcinoma--a case report. Coll Antropol; 2005 Dec;29(2):775-7
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A local recurrence of the tumor was found on the chest wall six years after the surgery.
  • Tumor excision was performed.
  • Histological analysis pointed at a ductal invasive carcinoma with numerous parasites of Trichinella spiralis present within both the muscle and the tumor tissue.
  • The finding of parasites in the tumor tissue witnesses in favor of infestation, and the parasite morphology preserved in the tumor shows at the protective effects of the cysts, i.e. preventing parasite necrosis.
  • [MeSH-major] Breast Neoplasms / parasitology. Carcinoma, Ductal, Breast / parasitology. Neoplasm Recurrence, Local / parasitology. Trichinella spiralis. Trichinellosis / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16417199.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


54. Wolf G, Schindler S, Koch A, Abolmaali N: Diffusion-weighted MRI for tumour volume delineation: comparison with morphological MRI. J Med Imaging Radiat Oncol; 2010 Jun;54(3):194-201
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted MRI for tumour volume delineation: comparison with morphological MRI.
  • Diffusion-weighted magnetic resonance imaging (dwMRI) is sensitive to tissue microstructure on the cellular level and may therefore help to define biological tumour subvolumes and add complementary information to morphology-based cancer treatment protocols and therapy monitoring.
  • The purpose of this study was therefore to evaluate the potential of dwMRI as compared with morphological MRI (mMRI) for tumour volume delineation using a nude rat human tumour xenograft model.
  • Sixteen tumour-bearing rats (10 H1299, six FaDu) were examined with mMRI (T2-weighted true fast imaging with steady precession (TrueFISP), T1-weighted fast low angle shot (FLASH), T2-weighted dual echo steady state (DESS)) and echo-planar dwMRI in a clinical scanner at 1.5 T.
  • For each method, we compared tumour volume and intra- and inter-observer variability of tumour outer edge delineation (disregarding intra-tumoural structure) as well as tumour signal-to-noise ratio (SNR) and tumour-to-muscle contrast-to-noise ratio (CNR).
  • Tumours were visualised with significantly higher SNR and CNR in dwMRI.
  • Median tumour volumes as measured by dwMRI (3.5 cm(3)) and mMRI (TrueFISP: 3.3 cm(3); FLASH: 3.3 cm(3); DESS: 3.2 cm(3)) were not significantly different and significantly correlated.
  • In conclusion, dwMRI allows tumour delineation with overall volume estimation comparable with mMRI approaches but slightly higher observer variability.
  • Thus, besides tumour outline, it may potentially supplement morphology-based therapy planning and monitoring with additional biological information.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / pathology. Diffusion Magnetic Resonance Imaging / methods. Imaging, Three-Dimensional / methods. Lung Neoplasms / pathology
  • [MeSH-minor] Animals. Cell Line, Tumor. Humans. Male. Rats. Rats, Nude. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20598006.001).
  • [ISSN] 1754-9485
  • [Journal-full-title] Journal of medical imaging and radiation oncology
  • [ISO-abbreviation] J Med Imaging Radiat Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


55. Lassalle HP, Dumas D, Gräfe S, D'Hallewin MA, Guillemin F, Bezdetnaya L: Correlation between in vivo pharmacokinetics, intratumoral distribution and photodynamic efficiency of liposomal mTHPC. J Control Release; 2009 Mar 4;134(2):118-24

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The highest tumour to muscle ratios were observed at 6 and 15 h post-administration.
  • Progressive efflux from the vascular compartment was noted in favour of tumour parenchyma, which was almost completed at 15 h.
  • The best tumour response was obtained for a drug-light interval of 6 h, interval for which mTHPC was present in both endothelial and parenchyma cells.
  • Tumour and plasma concentrations however were far below their maximal values.
  • Based on these observations, we assume that the presence of mTHPC in both vasculature and tumour cells is required for optimal PDT efficacy.
  • [MeSH-major] Liposomes / administration & dosage. Mammary Neoplasms, Animal / drug therapy. Mesoporphyrins / pharmacokinetics. Mesoporphyrins / therapeutic use. Photochemotherapy. Photosensitizing Agents / pharmacokinetics. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] 1,2-Dipalmitoylphosphatidylcholine / administration & dosage. Animals. Female. Mice. Mice, Nude. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / pathology. Phosphatidylglycerols / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19100297.001).
  • [ISSN] 1873-4995
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Liposomes; 0 / Mesoporphyrins; 0 / Phosphatidylglycerols; 0 / Photosensitizing Agents; 2644-64-6 / 1,2-Dipalmitoylphosphatidylcholine; FU21S769PF / temoporfin; VA9U6BR3SB / 1,2-dipalmitoylphosphatidylglycerol
  •  go-up   go-down


56. Knuuttila A, Jee KJ, Taskinen E, Wolff H, Knuutila S, Anttila S: Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch; 2006 Feb;448(2):135-41
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.
  • We examined 14 spindle cell tumours of the pleura that were sent to a Mesothelioma Panel for re-evaluation after a primary suspicion of mesothelioma.
  • Final diagnoses were eight sarcomatoid mesotheliomas (SM) and six non-mesotheliomas: two pulmonary sarcomatoid carcinomas, an epithelioid hemangioendothelioma, a malignant solitary fibrous tumour, a malignant pleural smooth muscle tumour and an extraskeletal osteosarcoma.
  • Seven of the eight SM and two of the other six tumours presented with unilateral pleural effusion, dyspnoea, and chest pain, which are characteristic clinical findings in malignant mesothelioma.
  • No single antibody used in the immunohistochemistry separated SM from other tumour types.
  • Losses of 4p11-p13/p15 and 4q occurred in combination in four out of five SM with detectable chromosomal changes, but neither was found in any of the other tumours.
  • Similarly, in the case of a cytokeratin-negative tumour, CGH analysis may disclose chromosomal changes characteristic of sarcomas or mesotheliomas.
  • [MeSH-major] Mesothelioma / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Calbindin 2. Chromosome Aberrations. Diagnosis, Differential. Female. Genome, Human. Humans. Immunohistochemistry. Keratins / analysis. Male. Middle Aged. Nucleic Acid Hybridization / methods. S100 Calcium Binding Protein G / analysis. Survival Analysis. Vimentin / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16170537.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


57. Russell ST, Siren PM, Siren MJ, Tisdale MJ: The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate. Br J Cancer; 2010 Mar 2;102(5):833-6
Hazardous Substances Data Bank. ZINC, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of zinc in the anti-tumour and anti-cachectic activity of D-myo-inositol 1,2,6-triphosphate.
  • BACKGROUND: D-myo-inositol-1,2,6-triphosphate (alpha-trinositol, AT) is a polyanionic molecule capable of chelating divalent metal ions with anti-tumour and anti-cachectic activity in a murine model.
  • METHODS: To investigate the role of zinc in this process, mice bearing cachexia-inducing MAC16 tumour were treated with AT, with or without concomitant administration of ZnSO(4).
  • RESULTS: At a dose of 40 mg kg(-1), AT effectively attenuated both weight loss and growth of the MAC16 tumour, and both effects were attenuated by co-administration of Zn(2+).
  • The concentration of zinc in gastrocnemius muscle increased with increasing weight loss, whereas administration of AT decreased the levels of zinc in plasma, skeletal muscle and tumour, which were restored back to control values after administration of ZnSO(4).
  • CONCLUSION: These results suggest that zinc is important in both tumour growth and cachexia in this animal model.
  • [MeSH-major] Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Cachexia / drug therapy. Inositol Phosphates / pharmacology. Neoplasms, Experimental / drug therapy. Trace Elements / pharmacology. Zinc / pharmacology
  • [MeSH-minor] Animals. Disease Models, Animal. Male. Mice. Weight Loss / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1987 Mar;78(3):539-46 [3546909.001]
  • [Cites] Am J Pathol. 1986 Mar;122(3):421-32 [3953767.001]
  • [Cites] Biol Trace Elem Res. 1994 Mar;40(3):295-308 [7517167.001]
  • [Cites] J Biol Chem. 2004 Dec 10;279(50):51804-16 [15355987.001]
  • [Cites] Cell Signal. 2007 Mar;19(3):538-46 [17008051.001]
  • [Cites] J Biol Chem. 2007 Mar 9;282(10):7087-97 [17213191.001]
  • [Cites] J Cell Biol. 2007 May 21;177(4):637-45 [17502426.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18636-41 [18003899.001]
  • [Cites] Cancer Sci. 2008 Aug;99(8):1515-22 [18754861.001]
  • [Cites] Carcinogenesis. 2008 Sep;29(9):1692-700 [18310092.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Aug;64(3):517-27 [19112551.001]
  • [Cites] J Nutr. 2000 May;130(5S Suppl):1500S-8S [10801966.001]
  • [Cites] J Inorg Biochem. 2001 Mar;84(1-2):107-11 [11330468.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11749-54 [11573009.001]
  • [Cites] Exp Biol Med (Maywood). 2003 Jun;228(6):689-96 [12773700.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):49819-27 [12975376.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4523-30 [14612438.001]
  • [Cites] Cell. 2004 Oct 15;119(2):285-98 [15479644.001]
  • [Cites] In Vivo. 1987 May-Jun;1(3):131-40 [2979776.001]
  • (PMID = 20145616.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Inositol Phosphates; 0 / Trace Elements; J41CSQ7QDS / Zinc; VYF3049W3N / atrinositol
  • [Other-IDs] NLM/ PMC2833253
  •  go-up   go-down


58. Janczak M, Kapuściński J, Olasik EM, Rózalski M, Płachcińska A, Kuśmierek J: Biodistribution of two (131)I-IMBA preparations, differently labelled, in mice with experimental B16 melanoma tumours. Nucl Med Rev Cent East Eur; 2008;11(2):48-52
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biodistribution of two (131)I-IMBA preparations, differently labelled, in mice with experimental B16 melanoma tumours.
  • Biodistribution of the injected compound was followed in mice with experimentally induced B16 melanoma tumours, and tumour/ tissue ratios were studied as a function of time post administration.
  • The biodistribution of (131)I-IMBA in C57 Black mice was studied in animals with experimentally induced B16 mice melanoma tumours.
  • RESULTS: The mean labelling efficiency exceeded 95 and 80 % for methods I and II, respectively, at radiochemical purity > 95% in both cases. (131)I-IMBA was vividly cumulated by melanoma tumours in mice.
  • At 24-hours post (131)I-IMBA administration the values of tumour /non-tumour ratios for the compound labelled by method II reached the following values: tumour/liver 10 +/- 3, tumour/lung 15 +/- 12, tumour/blood 153 +/- 39, tumour/intestines 176 +/- 26, tumour/kidneys 270 +/- 107, and tumour/muscle 448 +/- 82.
  • CONCLUSIONS: High values of tumour/non-tumour ratios indicate that (131)I-IMBA could be a promising radiopharmaceutical for clinical diagnosis (staging) of melanomas in humans.
  • [MeSH-minor] Animals. Cell Line, Tumor. Female. Metabolic Clearance Rate. Mice. Mice, Inbred C57BL. Organ Specificity. Radiopharmaceuticals / chemical synthesis. Radiopharmaceuticals / pharmacokinetics. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585454.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Benzamides; 0 / Iodobenzenes; 0 / N-(2-diethylaminoethyl)-3-iodo-4-methoxybenzamide; 0 / Radiopharmaceuticals
  •  go-up   go-down


59. Wiercioch R, Mirowski M, Balcerczak E, Byszewska E, Wierzbicki R: Uptake of radiolabelled endomorphins by experimental mammary adenocarcinoma. Nucl Med Rev Cent East Eur; 2005;8(1):1-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of this study was to examine the accumulation of endomorphin-1 (Tyr-Pro-Trp-Phe-NH2) and endomorphin- 2 (Tyr-Pro-Phe-Phe-NH2) labelled with radioiodine in tumour-bearing C3H/Bi mice.
  • The expression of the micro-opioid receptor in the tumours was confirmed by cross-linking assay and by RT- PCR technique.
  • RESULTS: The endomorphins showed relatively high tumour accumulation - about 5.2% of dose/g tissue for endomorphin-1 and about 3.8% for endomorphin-2.
  • The ratio of tumour to muscle for endomorphin-2 reached the highest value (12.7) six hours after injection.
  • The cross-linking assay of [125I]-labelled peptides with membranes, isolated from the mouse adenocarcinoma, followed by electrophoresis and autoradiography revealed the presence of a radioactive complex with molecular weight of about 65 kDa.
  • This complex was detectable by polyclonal antibodies raised against the N-terminal end of a micro-opioid receptor.
  • CONCLUSIONS: Endomorphin-1 and 2 have shown a high affinity to the m-opioid receptor present in mouse mammary adenocarcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Animals. Autoradiography. Cell Membrane / metabolism. Cross-Linking Reagents / pharmacology. Female. Kinetics. Ligands. Mammary Neoplasms, Experimental / pathology. Mice. Mice, Inbred C3H. Neoplasm Transplantation. Peptides / chemistry. Protein Binding. Receptors, Opioid, mu / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15977139.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Iodine Radioisotopes; 0 / Ligands; 0 / Oligopeptides; 0 / Peptides; 0 / Receptors, Opioid, mu; 0 / endomorphin 1; 0 / endomorphin 2
  •  go-up   go-down


60. Hu J, Zhang YX, Lan XL, Qin GM, Zhang J, Hu ZH: An imaging study using laminin peptide 99mTc-YIGSR in mice bearing Ehrlich ascites tumour. Chin Med J (Engl); 2005 May 5;118(9):753-8
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An imaging study using laminin peptide 99mTc-YIGSR in mice bearing Ehrlich ascites tumour.
  • The purpose is to evaluate the usefulness of (99m)Tc-YIGSR, a novel tumour radiotracer, in the receptor imaging of Ehrlich ascites tumour.
  • METHODS: Using S-acetly-NH3-MAG3 as chelate, YIGSR, a pentapeptide from laminin, was tagged with (99m)Tc. (99m)Tc-YIGSR was detected in the tumour group bearing Ehrlich ascites tumour and blocked group.
  • Tumour, normal, inflammatory and blocked groups were imaged.
  • The imaging findings showed tumour tissue accumulated initial radioactivity at fifteen minutes after injection in the tumour group, and the uptake increased to peak at three hours with a tumour/muscle ratio (T/M) of 11.36, then cleared slowly to a T/M of 7.50 at eight hours.
  • The tumour uptake of radiotracer in blocked group was significantly lower with T/M of 4.61 at three hours and 0.89 at eight hours.
  • Compared with inflammatory group and control obstructive group, the ratio of T/M in tumour group was significantly different (P < 0.001).
  • CONCLUSIONS: Using S-acetly-NH3-MAG3, we radiolabelled YIGSR with (99m)Tc. (99m)Tc-YIGSR possesses many merits of tumour imaging: rapid visualization, high sensitivity and specificity, and satisfactory target/nontarget ratio.
  • Our data suggest (99m)Tc-YIGSR is a promising tumour radiotracer.
  • [MeSH-major] Carcinoma, Ehrlich Tumor / radionuclide imaging. Laminin. Oligopeptides. Radiopharmaceuticals. Technetium
  • [MeSH-minor] Animals. Female. Mice. Technetium Tc 99m Mertiatide. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15899138.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Laminin; 0 / Oligopeptides; 0 / Radiopharmaceuticals; 0 / laminin 1; 110590-64-2 / tyrosyl-isoleucyl-glycyl-seryl-arginine; 36ITO9SKQJ / Technetium Tc 99m Mertiatide; 7440-26-8 / Technetium
  •  go-up   go-down


61. Crossland H, Constantin-Teodosiu D, Gardiner SM, Constantin D, Greenhaff PL: A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle. J Physiol; 2008 Nov 15;586(22):5589-600
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A potential role for Akt/FOXO signalling in both protein loss and the impairment of muscle carbohydrate oxidation during sepsis in rodent skeletal muscle.
  • Sepsis causes muscle atrophy and insulin resistance, but the underlying mechanisms are unclear.
  • Therefore, the present study examined the effects of lipopolysaccharide (LPS)-induced endotoxaemia on the expression of Akt, Forkhead Box O (FOXO) and its downstream targets, to identify any associations between changes in FOXO-dependent processes influencing muscle atrophy and insulin resistance during sepsis.
  • Animals were terminally anaesthetized and the extensor digitorum longus muscles from both hindlimbs were removed and snap-frozen.
  • LPS infusion induced increases in muscle tumour necrosis factor-alpha (8.9-fold, P < 0.001) and interleukin-6 (8.4-fold, P < 0.01), paralleled by reduced insulin receptor substrate-1 mRNA expression (-0.7-fold, P < 0.01), and decreased Akt1 protein and cytosolic FOXO1 and FOXO3 phosphorylation.
  • These changes were accompanied by significant increases in muscle atrophy F-box mRNA (5.5-fold, P < 0.001) and protein (2-fold, P < 0.05) expression, and pyruvate dehydrogenase kinase 4 mRNA (15-fold, P < 0.001) and protein (1.6-fold, P < 0.05) expression.
  • There was a 29% reduction in the muscle protein: DNA ratio, a 56% reduction in pyruvate dehydrogenase complex (PDC) activity (P < 0.05), and increased glycogen degradation and lactate accumulation.
  • The findings of this study suggest a potential role for Akt/FOXO in the simultaneous impairment of carbohydrate oxidation, at the level of PDC, and up-regulation of muscle protein degradation, in LPS-induced endotoxaemia.

  • MedlinePlus Health Information. consumer health - Sepsis.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1998 Jul 10;273(28):17680-8 [9651365.001]
  • [Cites] Br J Pharmacol. 1995 Nov;116(5):2487-95 [8581289.001]
  • [Cites] Biotechniques. 1999 Feb;26(2):202-4, 206 [10023525.001]
  • [Cites] Mol Cell Biochem. 1999 Aug;198(1-2):113-8 [10497885.001]
  • [Cites] J Biol Chem. 2005 Jan 28;280(4):2847-56 [15531760.001]
  • [Cites] Diabetes. 2004 Apr;53(4):899-910 [15047604.001]
  • [Cites] Cell. 2004 Apr 30;117(3):399-412 [15109499.001]
  • [Cites] Intensive Care Med. 2004 May;30(5):748-56 [14991101.001]
  • [Cites] Mol Cell. 2004 May 7;14(3):395-403 [15125842.001]
  • [Cites] Nat Med. 2004 Jun;10(6):584-5 [15170202.001]
  • [Cites] Cell. 2004 Oct 15;119(2):285-98 [15479644.001]
  • [Cites] Scand J Clin Lab Invest. 1974 Apr;33(2):109-20 [4852173.001]
  • [Cites] Arch Surg. 1987 Feb;122(2):228-33 [3545143.001]
  • [Cites] Diabetes. 2005 Oct;54(10):2939-45 [16186396.001]
  • [Cites] Diabetes. 2006 Aug;55(8):2311-7 [16873695.001]
  • [Cites] Endocrinology. 2006 Sep;147(9):4160-8 [16777975.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2006 Nov;291(5):E1044-50 [16803854.001]
  • [Cites] Endocr Rev. 2006 Dec;27(7):728-35 [17018837.001]
  • [Cites] Crit Care Clin. 2007 Jan;23(1):21-34 [17307114.001]
  • [Cites] Clin Sci (Lond). 2007 Jul;112(9):499-506 [17117920.001]
  • [Cites] Exp Physiol. 2007 May;92(3):561-73 [17272355.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E453-9 [17505052.001]
  • [Cites] J Physiol. 2007 Aug 15;583(Pt 1):381-90 [17540700.001]
  • [Cites] Cell Metab. 2007 Nov;6(5):376-85 [17983583.001]
  • [Cites] J Physiol. 2008 Mar 15;586(6):1767-75 [18218678.001]
  • [Cites] EMBO J. 2008 Apr 23;27(8):1266-76 [18354498.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E46-54 [18430968.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Dec;24(6):507-17 [9888161.001]
  • [Cites] Metabolism. 2000 Jun;49(6):689-91 [10877190.001]
  • [Cites] Clin Sci (Lond). 2000 Oct;99(4):321-8 [10995598.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):9-17 [11141219.001]
  • [Cites] Crit Care Med. 2001 Jul;29(7):1303-10 [11445675.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1704-8 [11679633.001]
  • [Cites] Nature. 2002 Aug 15;418(6899):797-801 [12181572.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):885-91 [12490963.001]
  • [Cites] FEBS Lett. 2003 Jun 5;544(1-3):214-7 [12782319.001]
  • [Cites] Biochem J. 2003 Oct 15;375(Pt 2):365-71 [12820900.001]
  • [Cites] FASEB J. 2004 Jan;18(1):39-51 [14718385.001]
  • [Cites] J Clin Invest. 1996 Jan 15;97(2):339-48 [8567953.001]
  • [Cites] Science. 1996 Feb 2;271(5249):665-8 [8571133.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2714-8 [8610106.001]
  • [Cites] Crit Care Med. 1996 Apr;24(4):575-83 [8612406.001]
  • [Cites] Shock. 1996 Aug;6(2):89-94 [8856841.001]
  • [Cites] Am J Physiol. 1997 Mar;272(3 Pt 2):R849-56 [9087646.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):197-203 [9202072.001]
  • [Cites] Biochem J. 1998 Jan 1;329 ( Pt 1):191-6 [9405293.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5315-22 [9478990.001]
  • [Cites] Endocrinology. 2005 Jun;146(6):2726-35 [15746249.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Oct;37(10):1974-84 [16087388.001]
  • [Cites] Metabolism. 1990 Oct;39(10):1096-107 [2215256.001]
  • [Cites] Clin Sci (Lond). 1991 Aug;81(2):249-56 [1716189.001]
  • [Cites] Anal Biochem. 1991 Nov 1;198(2):347-51 [1799221.001]
  • [CommentIn] J Physiol. 2008 Nov 15;586(22):5285 [19011130.001]
  • (PMID = 18818241.001).
  • [ISSN] 1469-7793
  • [Journal-full-title] The Journal of physiology
  • [ISO-abbreviation] J. Physiol. (Lond.)
  • [Language] ENG
  • [Grant] United Kingdom / Biotechnology and Biological Sciences Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Foxo3a protein, rat; 0 / Muscle Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Messenger; 147604-79-3 / Foxo1 protein, rat; EC 2.7.11.1 / Akt1 protein, rat; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.2 / pyruvate dehydrogenase (acetyl-transferring) kinase; EC 6.3.2.19 / Fbxo32 protein, rat; EC 6.3.2.19 / SKP Cullin F-Box Protein Ligases
  • [Other-IDs] NLM/ PMC2655379
  •  go-up   go-down


62. Christian N, Bol A, De Bast M, Labar D, Lee J, Mahy P, Grégoire V: Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model. Eur J Nucl Med Mol Imaging; 2007 Sep;34(9):1348-54
Hazardous Substances Data Bank. SPIRONOLACTONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.
  • Using the PET tracer [18F]EF3 in mice, tumour-to-muscle ratios ranging from 1.3 to 3.5 were observed.
  • This study investigated the impact of various interventions aimed at increasing [18F]EF3 elimination, thus potentially increasing the tumour-to-noise ratio in mice, by increasing the renal filtration rate (spironolactone, furosemide), decreasing tubular re-absorption (metronidazole, ornidazole, amino acid solution) or stimulating gastro-intestinal elimination (phenobarbital).
  • Regions of interest were delineated around the tumour, bladder, heart, liver and leg muscle.
  • Radioactivity was expressed as a percentage of injected activity per gram of tissue.
  • Phenobarbital significantly increased the liver concentration and decreased radioactivity in blood and muscle without affecting the tracer uptake in tumour.
  • Consequently, a small but non-significant increase in tumour-to-noise ratio was observed.
  • Although some effects were observed with other drugs, they did not modify the tumour-to-noise ratio.
  • CONCLUSION: Only phenobarbital induced a trend toward an increased tumour-to-noise ratio that could possibly be tested in the clinical situation.
  • [MeSH-major] Neoplasms / drug therapy. Neoplasms / pathology. Nitroimidazoles / pharmacology. Radiopharmaceuticals / pharmacology
  • [MeSH-minor] Animals. Anoxia. Area Under Curve. Liver / metabolism. Male. Mice. Mice, Inbred C3H. Ornidazole / pharmacology. Positron-Emission Tomography / methods. Spironolactone / pharmacology. Time Factors. Tissue Distribution. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17334763.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-(2-nitroimidazol-1-yl)-N-(3,3,3-trifluoropropyl)-acetamide; 0 / Nitroimidazoles; 0 / Radiopharmaceuticals; 27O7W4T232 / Spironolactone; 62XCK0G93T / Ornidazole
  •  go-up   go-down


63. Kefeli M, Yildiz L, Kaya FC, Aydin O, Kandemir B: Fascin expression in uterine smooth muscle tumors. Int J Gynecol Pathol; 2009 Jul;28(4):328-33
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fascin expression in uterine smooth muscle tumors.
  • SUMMARY: The diagnosis of malignant, uncertain malignant potential, and benign uterine smooth muscle tumors is derived from histologic criteria such as tumor cell necrosis, mitotic activity, and cytologic atypia.
  • In this study, we compared fascin expression in cases of leiomyoma, leiomyoma variants (LVs), uterine smooth muscle tumor of uncertain malignant potential (STUMP), and LMS, and sought to determine the potential role of fascin in differential diagnosis.
  • Fascin expression was investigated through the immunohistochemistry of paraffin-embedded tissue in 79 cases of uterine smooth muscle tumor including 22 usual leiomyoma, 31 LV, 4 STUMP, and 22 LMS cases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carrier Proteins / biosynthesis. Leiomyoma / pathology. Leiomyosarcoma / pathology. Microfilament Proteins / biosynthesis. Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483633.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  •  go-up   go-down


64. Souvatzoglou M, Grosu AL, Röper B, Krause BJ, Beck R, Reischl G, Picchio M, Machulla HJ, Wester HJ, Piert M: Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging; 2007 Oct;34(10):1566-75
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumour hypoxia imaging with [18F]FAZA PET in head and neck cancer patients: a pilot study.
  • This study was performed to evaluate the feasibility of use of (18)F-labelled fluoroazomycin arabinoside ([(18)F]FAZA) for clinical PET imaging of tumour hypoxia.
  • Standardised uptake values (SUVs) and tumour-to-muscle (T/M) ratios were calculated in tumour and normal tissues.
  • Also, the tumour volume displaying a T/M ratio >1.5 was determined.
  • At 2 h p.i., the tumour SUV(max) and SUV(mean) were found to be 2.3 +/- 0.5 (range 1.5-3.4) and 1.4 +/- 0.3 (range 1.0-2.1), respectively.
  • The tumour volume displaying a T/M ratio above 1.5 was highly variable.
  • At 2 h p.i., [(18)F]FAZA organ distribution was determined as follows: kidney > gallbladder > liver > tumour > muscle > bone > brain > lung.
  • [MeSH-major] Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / radionuclide imaging. Nitroimidazoles / pharmacokinetics. Oxygen / metabolism. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1563-5 [17598110.001]
  • (PMID = 17447061.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nitroimidazoles; 0 / Radiopharmaceuticals; 0 / fluoroazomycin arabinoside; S88TT14065 / Oxygen
  •  go-up   go-down


65. Molina-Trinidad EM, de Murphy CA, Jung-Cook H, Stack EM, Pedraza-Lopez M, Morales-Marquez JL, Serrano GV: Therapeutic 188Re-lanreotide: determination of radiopharmacokinetic parameters in rats. J Pharm Pharmacol; 2010 Apr;62(4):456-61
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The radiopharmacokinetic parameters of the therapeutic radiopharmaceutical (188)Re-lanreotide were compared in rats implanted with hepatocarcinoma tumours (n= 18) and healthy rats (n= 18).
  • The activity per gram of tissue (%IA/g) was calculated and the radiopharmacokinetic parameters determined.
  • The tumour/organ ratios after 24 h were 11.20 for tumour/muscle, 8.00 for tumour/liver and 7.72 for tumour/bone.
  • This may be beneficial in the diagnosis and therapy of metastatic lesions in patients with cancer.
  • [MeSH-major] Antineoplastic Agents / pharmacokinetics. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Peptides, Cyclic / pharmacokinetics. Radiopharmaceuticals / pharmacokinetics. Rhenium / pharmacokinetics. Somatostatin / analogs & derivatives
  • [MeSH-minor] Animals. Bone and Bones. Half-Life. Liver. Male. Muscles. Radioisotopes / pharmacokinetics. Radioisotopes / therapeutic use. Rats. Rats, Wistar. Reference Values. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20604834.001).
  • [ISSN] 2042-7158
  • [Journal-full-title] The Journal of pharmacy and pharmacology
  • [ISO-abbreviation] J. Pharm. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Peptides, Cyclic; 0 / Radioisotopes; 0 / Radiopharmaceuticals; 118992-92-0 / lanreotide; 51110-01-1 / Somatostatin; 7440-15-5 / Rhenium
  •  go-up   go-down


66. Autio A, Ujula T, Luoto P, Salomäki S, Jalkanen S, Roivainen A: PET imaging of inflammation and adenocarcinoma xenografts using vascular adhesion protein 1 targeting peptide 68Ga-DOTAVAP-P1: comparison with 18F-FDG. Eur J Nucl Med Mol Imaging; 2010 Oct;37(10):1918-25
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The aim of this study was to evaluate inflammation and tumour imaging with a vascular adhesion protein 1 (VAP-1) targeting peptide (68)Ga-DOTAVAP-P1 in comparison with (18)F-FDG.
  • METHODS: Rats with both subcutaneous human pancreatic adenocarcinoma xenografts and turpentine oil-induced acute sterile inflammation were evaluated by dynamic positron emission tomography (PET) and by digital autoradiography of tissue cryosections.
  • However, the tumour uptake of (68)Ga-DOTAVAP-P1 was low in contrast to prominent (18)F-FDG uptake.
  • The standardised uptake values of inflammation and tumours by PET were 1.1 +/- 0.4 (mean +/- SEM) and 0.4 +/- 0.1 for (68)Ga-DOTAVAP-P1 and 2.0 +/- 0.5 and 1.6 +/- 0.8 for (18)F-FDG, respectively.
  • In addition, PET studies showed inflammation to muscle and tumour to muscle ratios of 5.1 +/- 3.1 and 1.7 +/- 0.3 for (68)Ga-DOTAVAP-P1 and 6.2 +/- 0.7 and 4.6 +/- 2.2 for (18)F-FDG, respectively.
  • Immunohistochemistry revealed increased expression of luminal VAP-1 on the endothelium at the site of inflammation and low expression in the tumour CONCLUSION: The (68)Ga-DOTAVAP-P1 PET was able to visualise inflammation better than tumour, which was in accordance with the luminal expression of VAP-1 on vasculature in these experimental models.
  • [MeSH-minor] Animals. Cell Line, Tumor. Gallium Radioisotopes. Gene Expression Regulation, Neoplastic. Humans. Inflammation / metabolism. Inflammation / radionuclide imaging. Male. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / radionuclide imaging. Rats. Skin Diseases / metabolism. Skin Diseases / radionuclide imaging

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20523988.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Gallium Radioisotopes; 0 / Heterocyclic Compounds, 1-Ring; 0 / Peptides; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 60239-18-1 / 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; EC 1.4.3.21 / AOC3 protein, human; EC 1.4.3.21 / Amine Oxidase (Copper-Containing)
  •  go-up   go-down


67. Gupte C, Butt SH, Tirabosco R, Saifuddin A: Angioleiomyoma: magnetic resonance imaging features in ten cases. Skeletal Radiol; 2008 Nov;37(11):1003-9
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Angioleiomyoma is a rare, benign smooth muscle tumour arising from the tunica media of small veins and arteries and can occur anywhere in the body.
  • MATERIALS AND METHODS: A retrospective study of the clinical presentation, MRI appearances and histological findings of ten angioleiomyomas presenting as extremity soft tissue masses.
  • The lesion was isointense to muscle on T1-weighted spin echo images with heterogeneous increased internal T2W/short tau inversion recovery (STIR) signal intensity, which commonly appeared as multiple linear or branching areas of hyperintensity.
  • Angioleiomyoma should be considered in the differential diagnosis of a superficial mass in the hand or foot, particularly when characteristic linear or branching hyperintensity is seen on T2W or STIR images.
  • [MeSH-major] Angiomyoma / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18581112.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


68. Jia ZY, Deng HF, Pu MF, Luo SZ: Rhenium-188 labelled meso-tetrakis[3,4-bis(carboxymethyleneoxy)phenyl] porphyrin for targeted radiotherapy: preliminary biological evaluation in mice. Eur J Nucl Med Mol Imaging; 2008 Apr;35(4):734-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In nude mice, more than 4.4 and 6.1% uptake per gram of tumour (%ID g(-1)) at 8 h postinjection was in melanoma and hepatoma, respectively; this remained as high levels after 24 h as 4.6 and 6.5%, respectively.
  • At 8 h, the tumour/blood and tumour/muscle (T/M) ratios in melanomas and hepatoma bearing mice were 7.3, 13,and 7.0, 20, respectively.
  • CONCLUSION: The results obtained in this study indicate that (188)Re-T(3,4)CPP has better tumour affinity and retainable accumulation characteristics in carcinoma which can potentially be used for tumour-targeted radiotherapy.
  • [MeSH-minor] Animals. Disease Models, Animal. Drug Stability. Hydrogen-Ion Concentration. Kinetics. Liver Neoplasms / radiotherapy. Liver Neoplasms, Experimental / radiotherapy. Melanoma / radiotherapy. Mice. Mice, Inbred BALB C. Mice, Nude. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18193220.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organometallic Compounds; 0 / Porphyrins; 0 / Radiopharmaceuticals; 0 / rhenium meso-tetrakis(3,4-bis(carboxymethyleneoxy)phenyl)porphyrin; 7440-15-5 / Rhenium
  •  go-up   go-down


69. Rybczynska AA, Elsinga PH, Sijbesma JW, Ishiwata K, de Jong JR, de Vries EF, Dierckx RA, van Waarde A: Steroid hormones affect binding of the sigma ligand 11C-SA4503 in tumour cells and tumour-bearing rats. Eur J Nucl Med Mol Imaging; 2009 Jul;36(7):1167-75
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Steroid hormones affect binding of the sigma ligand 11C-SA4503 in tumour cells and tumour-bearing rats.
  • In addition, sigma receptors are strongly overexpressed in many tumours.
  • Tumour-bearing male rats were repeatedly treated with pentobarbital (a condition known to result in reduction of endogenous steroid levels) or injected with progesterone.
  • Intraperitoneally administered progesterone reduced tumour uptake and tumour-to-muscle contrast (36%).
  • Repeated treatment of animals with pentobarbital increased the PET standardized uptake value of (11)C-SA4503 in tumour (16%) and brain (27%), whereas the kinetics of blood pool radioactivity was unaffected.
  • Since not only increases but also decreases of steroid levels affect ligand binding, a considerable fraction of the sigma-1 receptor population in cultured tumour cells or tumour-bearing animals is normally occupied by endogenous steroids.
  • [MeSH-major] Hormones / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Piperazines / metabolism. Receptors, sigma / metabolism. Steroids / metabolism
  • [MeSH-minor] Animals. Binding, Competitive. Cell Line, Tumor. Disease Models, Animal. Ligands. Positron-Emission Tomography. Rats. Tissue Distribution

  • MedlinePlus Health Information. consumer health - Hormones.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosci Res. 1996 Dec 15;46(6):734-43 [8978508.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3774-8 [7731982.001]
  • [Cites] J Nucl Med. 2004 Nov;45(11):1939-45 [15534066.001]
  • [Cites] Cell Mol Life Sci. 2005 May;62(9):1003-14 [15798892.001]
  • [Cites] Acta Neurol Scand. 2005 Aug;112(2):103-7 [16008536.001]
  • [Cites] Synapse. 2006 Mar 1;59(3):152-61 [16342057.001]
  • [Cites] J Nucl Med. 2006 Jan;47(1):150-4 [16391199.001]
  • [Cites] Ann Nucl Med. 2005 Dec;19(8):701-9 [16444997.001]
  • [Cites] Neuropsychopharmacology. 2006 Jul;31(7):1431-43 [16132061.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Aug;84(4):581-97 [16945406.001]
  • [Cites] Curr Pharm Des. 2006;12(30):3857-76 [17073684.001]
  • [Cites] Neuroimage. 2007 Mar;35(1):1-8 [17240168.001]
  • [Cites] Biochemistry. 2007 Mar 20;46(11):3532-42 [17315983.001]
  • [Cites] Synapse. 2007 Jul;61(7):540-6 [17447254.001]
  • [Cites] J Nucl Med. 2007 Aug;48(8):1320-6 [17631546.001]
  • [Cites] Mol Pharmacol. 2007 Oct;72(4):921-33 [17622576.001]
  • [Cites] Biol Psychiatry. 2007 Oct 15;62(8):878-83 [17662961.001]
  • [Cites] Ann Nucl Med. 2008 Apr;22(3):151-6 [18498028.001]
  • [Cites] Neoplasma. 2008;55(4):294-8 [18505339.001]
  • [Cites] Eur J Nucl Med. 1996 Oct;23(10):1409-15 [8781149.001]
  • [Cites] Br J Cancer. 1999 Nov;81(6):925-33 [10576647.001]
  • [Cites] Jpn J Pharmacol. 1999 Oct;81(2):125-55 [10591471.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1223-32 [10735510.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Aug;298(2):703-10 [11454934.001]
  • [Cites] Nucl Med Biol. 2003 Apr;30(3):273-84 [12745019.001]
  • [Cites] Pharm Res. 2004 Aug;21(8):1382-9 [15359572.001]
  • [Cites] J Androl. 1983 Sep-Oct;4(5):293-7 [6415026.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Apr;83(8):2496-500 [3458212.001]
  • [Cites] Eur J Cancer Clin Oncol. 1987 Jun;23(6):745-8 [3653192.001]
  • [Cites] Science. 1988 Apr 8;240(4849):219-21 [2832949.001]
  • [Cites] Cancer. 1992 May 1;69(9):2306-10 [1562977.001]
  • [Cites] Trends Pharmacol Sci. 1992 Mar;13(3):85-6 [1315463.001]
  • [Cites] Neuroendocrinology. 1993 Mar;57(3):559-65 [8391666.001]
  • [Cites] Eur J Pharmacol. 1994 Jun 15;268(1):9-18 [7925616.001]
  • [Cites] Cancer Res. 1995 Jan 15;55(2):408-13 [7812973.001]
  • [Cites] J Neurosci. 1995 Jan;15(1 Pt 1):117-34 [7823122.001]
  • [Cites] Endocrinology. 1995 Mar;136(3):924-32 [7867601.001]
  • [Cites] Cancer Res. 1997 Jan 1;57(1):156-61 [8988058.001]
  • (PMID = 19247652.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hormones; 0 / Ligands; 0 / Piperazines; 0 / Receptors, sigma; 0 / SA 4503; 0 / Steroids
  • [Other-IDs] NLM/ PMC2691528
  •  go-up   go-down


70. Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, Eble M, Buell U, Reinartz P: FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging; 2006 Dec;33(12):1426-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG--a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer.
  • PURPOSE: Experimental data suggest that the accumulation of [(18)F]fluorodeoxyglucose (FDG) in malignant tumours is related to regional hypoxia.
  • The aim of this study was to evaluate the clinical potential of FDG positron emission tomography (PET) to assess tumour hypoxia in comparison with [(18)F]fluoromisonidazole (FMISO) PET and pO(2)-polarography.
  • RESULTS: We observed a moderate correlation of the maximum standardised uptake value (SUV) of FDG with the tumour to blood ratio of FMISO at 2 h (R=0.53, p<0.05).
  • However, SUV of FDG was similar in hypoxic and normoxic tumours as defined by pO(2)-polarography (6.9+/-3.2 vs 6.2+/-3.0, NS), and the FDG uptake was not correlated with the results of pO(2)-polarography.
  • The retention of FMISO was significantly higher in hypoxic tumours than in normoxic tumours (tumour to muscle ratio at 2 h: 1.8+/-0.4 vs 1.4+/-0.1, p<0.05), and the FMISO tumour to muscle ratio showed a strong correlation with the frequency of pO(2) readings <or=5 mmHg (R=0.80, p<0.001).
  • CONCLUSION: These results support the hypothesis that tumour hypoxia has an effect on glucose metabolism.
  • However, other factors affecting FDG uptake may be more predominant in chronic hypoxia, and thus FDG PET cannot reliably differentiate hypoxic from normoxic tumours.
  • [MeSH-major] Anoxia / metabolism. Fluorodeoxyglucose F18 / metabolism. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / pathology. Misonidazole / analogs & derivatives. Oxygen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Neoplasm Metastasis / radionuclide imaging. Polarography. Positron-Emission Tomography. Reference Standards

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. OXYGEN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16841141.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 13551-89-8 / fluoromisonidazole; 8FE7LTN8XE / Misonidazole; S88TT14065 / Oxygen
  •  go-up   go-down


71. Amant F, Moerman P, Vergote I: Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1210-2
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of an unusual problematic uterine smooth muscle neoplasm, emphasizing the prognostic importance of coagulative tumor cell necrosis.
  • Follow-up data of the clinical behavior of uterine smooth muscle tumors with low malignant potential are scarce.
  • We present a woman suffering from a uterine smooth muscle cell tumor with increased cellularity, absence of significant atypia, and two to three mitotic figures per 10 HPFs but with minimal focal coagulative tumor cell necrosis (CTCN).
  • These microscopic features are currently accepted to label the lesion as a "smooth muscle neoplasm of low malignant potential, limited experience."
  • After a disease-free survival of 4 years, two retroperitoneal tumors around the iliac vessels were extirpated.
  • Both tumors consisted of smooth muscle cells with mild to moderate atypia and a mitotic index of 5-10 per 10 HPFs but with multifocal and extensive CTCN.
  • These microscopic features were sufficient to establish the diagnosis of leiomyosarcoma.
  • This case adds to the limited experience of the clinical behavior of problematic uterine smooth muscle cell neoplasms and underscores the prognostic importance of CTCN.
  • [MeSH-major] Leiomyosarcoma / pathology. Neoplasm Recurrence, Local / pathology. Retroperitoneal Neoplasms / pathology. Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343216.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Koch CJ, Shuman AL, Jenkins WT, Kachur AV, Karp JS, Freifelder R, Dolbier WR Jr, Evans SM: The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake. Int J Radiat Biol; 2009 Dec;85(12):1137-47
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The radiation response of cells from 9L gliosarcoma tumours is correlated with [F18]-EF5 uptake.
  • PURPOSE: Tumour hypoxia affects cancer biology and therapy-resistance in both animals and humans.
  • The purpose of this study was to determine whether EF5 ([2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)-acetamide]) binding and/or radioactive drug uptake correlated with single-dose radiation response in 9L gliosarcoma tumours.
  • MATERIALS AND METHODS: Twenty-two 9L tumours were grown in male Fischer rats.
  • Rats were administered low specific activity (18)F-EF5 and their tumours irradiated and assessed for cell survival and hypoxia.
  • Hypoxia assays included EF5 binding measured by antibodies against bound-drug adducts and gamma counts of (18)F-EF5 tumour uptake compared with uptake by normal muscle and blood.
  • In six cases, uptake of tumour versus muscle was also assayed using images from a PET (positron emission tomography) camera (PENN G-PET).
  • RESULTS: The intertumoural variation in radiation response of 9L tumour-cells was significantly correlated with uptake of (18)F-labelled EF5 (i.e., including both bound and non-bound drug) using either tumour to muscle or tumour to blood gamma count ratios.
  • In the tumours where imaging was performed, there was a significant correlation between the image analysis and gamma count analysis.
  • Intertumoural variation in cellular radiation response of the same 22 tumours was also correlated with mean flow cytometry signal due to EF5 binding.
  • CONCLUSION: To our knowledge, this is the first animal model/drug combination demonstrating a correlation of radioresponse for tumour-cells from individual tumours with drug metabolism using either immunohistochemical or non-invasive techniques.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5721-6 [8242628.001]
  • [Cites] Radiother Oncol. 1993 Jul;28(1):69-71 [8234872.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):405-11 [8542599.001]
  • [Cites] Cancer Res. 1996 Mar 1;56(5):941-3 [8640781.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):372-8 [8707411.001]
  • [Cites] Int J Cancer. 1996 Sep 4;67(5):661-7 [8782655.001]
  • [Cites] Radiother Oncol. 1996 Oct;41(1):31-9 [8961365.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2922-8 [9230202.001]
  • [Cites] Nucl Med Biol. 1997 Oct;24(7):677-83 [9352540.001]
  • [Cites] Radiother Oncol. 1998 Aug;48(2):149-56 [9783886.001]
  • [Cites] J Nucl Med. 1999 Jan;40(1):177-83 [9935074.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1137-46 [10421548.001]
  • [Cites] Br J Cancer. 2004 Nov 29;91(11):1947-54 [15520822.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):253-60 [15695784.001]
  • [Cites] J Nucl Med. 2005 Apr;46(4):560-6 [15809476.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502 [15817355.001]
  • [Cites] IEEE Trans Med Imaging. 2005 Jul;24(7):844-52 [16011313.001]
  • [Cites] Mol Cancer Ther. 2005 Sep;4(9):1417-22 [16170034.001]
  • [Cites] Diabetes. 2006 Jan;55(1):13-8 [16380471.001]
  • [Cites] BMC Cancer. 2005;5:152 [16321146.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2098-104 [16648512.001]
  • [Cites] J Nucl Med. 2006 Jun;47(6):989-98 [16741309.001]
  • [Cites] Clin Cancer Res. 2006 Sep 15;12(18):5435-41 [17000677.001]
  • [Cites] Int J Radiat Biol. 2006 Oct;82(10):699-757 [17118889.001]
  • [Cites] J Nucl Med. 2007 Jun;48(6):973-80 [17536108.001]
  • [Cites] Cancer Metastasis Rev. 2007 Jun;26(2):225-39 [17440684.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Oct 1;69(2):541-51 [17869667.001]
  • [Cites] Radiother Oncol. 2008 Jan;86(1):30-4 [18061294.001]
  • [Cites] Radiat Res. 2008 Jun;169(6):677-88 [18494550.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:129S-48S [18523070.001]
  • [Cites] J Nucl Med. 2003 Aug;44(8):1340-9 [12902426.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Apr;31(4):513-20 [14722675.001]
  • [Cites] Br J Cancer. 2004 Jun 1;90(11):2232-42 [15150578.001]
  • [Cites] Cancer Clin Trials. 1980 Fall;3(3):237-51 [7438321.001]
  • [Cites] Radiat Res. 1980 Dec;84(3):529-41 [7454994.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 May;10(5):695-712 [6735758.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1749-53 [6237086.001]
  • [Cites] Cancer Res. 1987 Jan 1;47(1):319-22 [3024818.001]
  • [Cites] Cytometry. 1990;11(3):418-30 [2340776.001]
  • [Cites] Phys Med Biol. 2008 Aug 7;53(15):4153-67 [18635895.001]
  • [Cites] J Nucl Med. 2008 Dec;49(12):1944-51 [18997048.001]
  • [Cites] Radiat Res. 2008 Dec;170(6):677-90 [19138031.001]
  • [Cites] Radiat Res. 2000 Jan;153(1):84-92 [10630981.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):1005-17 [10705024.001]
  • [Cites] Appl Radiat Isot. 2001 Jan;54(1):73-80 [11144255.001]
  • [Cites] J Nucl Med. 2001 Feb;42(2):337-44 [11216534.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):587-96 [11173159.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Mar 15;49(4):1171-82 [11240261.001]
  • [Cites] J Nucl Med. 2001 Apr;42(4):655-61 [11337556.001]
  • [Cites] Radiat Res. 2001 Oct;156(4):388-98 [11554850.001]
  • [Cites] Cancer Chemother Pharmacol. 2001 Sep;48(3):177-87 [11592338.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1653-5 [11696634.001]
  • [Cites] Semin Nucl Med. 2001 Oct;31(4):321-9 [11710774.001]
  • [Cites] Methods Enzymol. 2002;352:3-31 [12125356.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):903-9 [12377344.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):259-66 [12552344.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1233-8 [12654432.001]
  • [Cites] Cancer Lett. 2003 May 30;195(1):1-16 [12767506.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):199-212 [1727119.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):45-50 [8438086.001]
  • [Cites] J Nucl Med. 1993 Jun;34(6):885-8 [8389842.001]
  • [Cites] Br J Cancer. 1995 Oct;72(4):869-74 [7547233.001]
  • (PMID = 19995239.001).
  • [ISSN] 1362-3095
  • [Journal-full-title] International journal of radiation biology
  • [ISO-abbreviation] Int. J. Radiat. Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087645; United States / NCI NIH HHS / CA / R01-CA87645
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS604353; NLM/ PMC4110891
  •  go-up   go-down


73. Atkins KA, Arronte N, Darus CJ, Rice LW: The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am J Surg Pathol; 2008 Jan;32(1):98-102
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Use of p16 in enhancing the histologic classification of uterine smooth muscle tumors.
  • BACKGROUND: Uterine smooth muscle tumors can usually be divided histologically into leiomyoma (L) and leiomyosarcoma (LMS).
  • Occasionally, the histologic features are indeterminate and classified as smooth muscle tumor of uncertain malignant potential (STUMP).
  • Additionally, 8 tumors originally classified as STUMP were evaluated for p16 expression and correlated to their clinical outcome.
  • METHODS: A tissue microarray was constructed and composed of 15 LMS, 8 STUMPs, 22 L, and 10 samples of normal myometrium. p16 expression was correlated with clinical outcome and histologic features.
  • Three of the tumors originally classified as STUMP developed metastatic disease and 2 of these tumors had strong, diffuse p16 positivity.
  • Histologically, these 2 cases were characterized by coagulative tumor cell necrosis and only mild cytologic atypia.
  • Histologically, tumors with coagulative tumor cell necrosis alone were clinically LMS.
  • In those cases in which the type of necrosis is uncertain (coagulative tumor cell vs. hyalinized), the addition of p16 may aid in discerning a subset of STUMP that should be classified as LMS.
  • [MeSH-major] Genes, p16. Leiomyoma / classification. Leiomyosarcoma / classification. Uterine Neoplasms / classification
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162776.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


74. Garnuszek P, Wiercioch R, Sztajer H, Karczmarczyk U, Mirowski M: Uptake of radiolabelled modified fragment of human alfa-fetoptrotein by experimental mammary adenocarcinoma: in vitro and in vivo studies. Nucl Med Rev Cent East Eur; 2005;8(1):6-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The aim of the study was to examine in vitro and in vivo binding of radiolabelled analogues of P149 peptide by experimental mammary adenocarcinoma with the intention of potential application for diagnosis and internal radiotherapy of tumours.
  • The biodistribution of P149-Q[125I]-Y was studied in experimental mammary tumours.
  • For in vitro experiments, extract from mouse mammary tumours were prepared and incubated with radioiodinated P149-QY peptide in the presence of a cross-linking reagent.
  • The biodistribution of P149-Q[125I]-Y studied in experimental mammary tumours revealed a higher pharmacokinetic rate in comparison with the whole radioiodinated AFP molecule.
  • A moderate uptake of P149-Q[125I]-Y in the tumour tissue was observed (3.2% ID/g at 30-min p.i.v).
  • However, a faster radioactivity clearance from blood and normal tissues resulted in an increase in the tumour/muscle (T/M) ratio, i.e. from 2.3 to 3.4 after 30 mins and 24 h p.i.v, respectively.
  • [MeSH-major] Adenocarcinoma / pathology. Iodine Radioisotopes / pharmacokinetics. Mammary Neoplasms, Experimental / pathology. alpha-Fetoproteins / pharmacokinetics
  • [MeSH-minor] Animals. Chromatography, High Pressure Liquid. Cross-Linking Reagents / pharmacology. Electrophoresis, Polyacrylamide Gel. Female. Humans. In Vitro Techniques. Mice. Peptides / chemistry. Radiopharmaceuticals / pharmacokinetics. Time Factors. Tissue Distribution

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15977140.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 0 / Iodine Radioisotopes; 0 / Peptides; 0 / Radiopharmaceuticals; 0 / alpha-Fetoproteins
  •  go-up   go-down


75. van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, Dingemans AM, Lalisang R, Brans B, Windhorst B, van Dongen GA, Kolb H, Zhang J, De Ruysscher D, Lambin P: PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging; 2010 Aug;37(9):1663-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Noninvasive PET imaging of tumour hypoxia could help in the selection of those patients who could benefit from chemotherapy or radiation with specific antihypoxic treatments such as bioreductive drugs or hypoxic radiosensitizers.
  • A study design with two dose steps was used in which a single dose of a maximum of 222 MBq (step 1) or 444 MBq (step 2) [(18)F]HX4 was injected.
  • PET/CT images of the largest tumour site were acquired 30, 60 and 120 min after injection.
  • The median tumour to muscle ratio 120 min after injection was 1.40 (range 0.63-1.98).
  • [MeSH-minor] Aged. Cell Hypoxia. Dose-Response Relationship, Drug. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoplasms / pathology. Neoplasms / radionuclide imaging. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20369236.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol; 0 / Nitroimidazoles; 0 / Triazoles
  •  go-up   go-down


76. Chen L, Yang B: Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol; 2008 Jul;27(3):326-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors.
  • However, the potential role of immunohistochemistry of p16, p53, and Ki-67 in the differential diagnosis of leiomyosarcoma and bizarre leiomyoma has not been well assessed.
  • We had immunohistochemically studied the expression of p16, p53, and Ki-67 proteins in 100 cases of uterine smooth muscle tumors, including 35 usual leiomyomas (LM), 13 cellular leiomyomas (CLM), 15 bizarre leiomyomas (BLM), 2 cases of smooth muscle tumor of uncertain malignant potential (STUMP), and 35 leiomyosarcoma (LMS).
  • [MeSH-major] Ki-67 Antigen / analysis. Leiomyoma / diagnosis. Leiomyosarcoma / diagnosis. Neoplasm Proteins / analysis. Tumor Suppressor Protein p53 / analysis. Uterine Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580309.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


77. Bodner-Adler B, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K: Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis. Gynecol Oncol; 2005 Jan;96(1):62-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of p16 protein in patients with uterine smooth muscle tumors: an immunohistochemical analysis.
  • OBJECTIVE: The loss of cell cycle control is a critical step in the development of neoplasia.
  • The p16 protein has been identified as a tumor suppressor protein, which binds specifically to the cyclin-dependent kinase CDK-4, inhibiting the catalytic activity of the CDK4-cyclin D complex, and thereby acts as a negative cell cycle regulator.
  • In the present study, we compared the expression of p16 protein in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP), and leiomyosarcoma (LMS).
  • METHODS: P16 expression was investigated by immunohistochemistry from paraffin-embedded tissue in 26 patients with leiomyoma, in 24 patients with STUMP, and in 21 patients with LMS.
  • No statistically significant correlation between p16 expression and clinical stage, age, vascular space involvement, and recurrence disease could be found in patients with LMS (P > 0.05).
  • Furthermore, p16 might be a useful immunohistochemical marker, which could help to distinguish cases of smooth muscle tumors in which histologic features are ambiguous or borderline, but the use of p16 in a diagnostic setting should await further clinical studies and clarification of the mechanisms.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Smooth Muscle Tumor / metabolism. Uterine Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Leiomyoma / metabolism. Leiomyoma / pathology. Leiomyoma / therapy. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Leiomyosarcoma / therapy. Middle Aged. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589581.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


78. Ip PP, Tse KY, Tam KF: Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy. Adv Anat Pathol; 2010 Mar;17(2):91-112
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas: a review of selected variants with emphasis on recent advances and unusual morphology that may cause concern for malignancy.
  • Uterine smooth muscle tumors are classified according to their morphologic features that include architecture, growth pattern, cellular characteristics and constituents of the intercellular stroma.
  • While terminologies used for the pathologic diagnosis of various subtypes may be eloquent and histologically accurate, some of these are confusing for the clinician and may also be open to interpretation by different pathologists: the labeling of atypical leiomyomas epitomizes this intricate system.
  • Clinically, it is probably more useful to classify them as either tumors with or tumors without recurrent and/or metastatic potential.
  • The term "atypical leiomyoma" has been used to label tumors that have a low risk of recurrence and is synonymous with benign tumors.
  • Variants of benign uterine smooth muscle tumors, such as mitotically active leiomyoma, cellular and highly cellular leiomyoma, epithelioid leiomyoma, and myxoid leiomyoma each have distinctive hallmarks that enable subclassification.
  • Tumors that have a dissecting growth pattern, with or without extrauterine extension, may mimic malignancy both grossly and microscopically.
  • The current review discusses the pathologic diagnosis of and terminology applied to selected variants of uterine smooth muscle tumors other than the ordinary leiomyomas and leiomyosarcomas with emphasis on unusual reported features that may indicate malignancy.
  • This includes an update on uterine smooth muscle tumor of uncertain malignant potential (STUMP), intravenous leiomyomatosis, benign metastasizing leiomyoma, and diffuse leiomyomatosis.
  • [MeSH-major] Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Leiomyoma / pathology. Leiomyoma, Epithelioid / pathology. Leiomyomatosis / pathology. Lung Neoplasms / secondary. Middle Aged. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20179432.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 156
  •  go-up   go-down


79. Yin X, Wu T, Yan Y, Zhang H, Bu H: Treatment for leiomyosarcoma and leiomyoma in children with HIV infection. Cochrane Database Syst Rev; 2010;(5):CD007665
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Smooth muscle tumour (SMT) composed of leiomyoma and leiomyosarcoma recently has been described in many HIV-infected children.
  • Although leiomyosarcoma accounts for only 2% to 4% of childhood soft tissue sarcomas, the prognosis is poor in HIV-infected compared with non-infected patients.
  • Currently, the optimal therapeutic strategy is controversial and there is a need to identify the efficacy and safety of different interventions for AIDS-associated SMT on overall survival and disease-free survival in children.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20464756.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 43
  •  go-up   go-down


80. Krause BJ, Souvatzoglou M, Herrmann K, Weber AW, Schuster T, Buck AK, Nawroth R, Weirich G, Treiber U, Wester HJ, Ziegler SI, Senekowitsch-Schmidtke R, Schwaiger M: [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model. Eur J Nucl Med Mol Imaging; 2010 Oct;37(10):1861-8
Hazardous Substances Data Bank. CHOLINE CHLORIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To determine choline uptake the images were analysed in terms of tumour-to-muscle (T/M) ratios.
  • Every week the size of the implanted tumour was determined with a sliding calliper.
  • RESULTS: The PC-3 tumours could be visualized by [(11)C]choline PET.
  • Metabolic changes occurred 1 week after therapy and preceded morphological changes of tumour size during therapy.
  • [MeSH-major] Biomarkers, Tumor. Choline. Prostatic Neoplasms / radionuclide imaging. Prostatic Neoplasms / therapy. Xenograft Model Antitumor Assays
  • [MeSH-minor] Animals. Carbon Radioisotopes. Cell Line, Tumor. Humans. Male. Mice. Positron-Emission Tomography. Taxoids / pharmacology. Taxoids / therapeutic use. Tomography, X-Ray Computed. Treatment Outcome. Tumor Burden / drug effects

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20512572.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carbon Radioisotopes; 0 / Taxoids; 15H5577CQD / docetaxel; N91BDP6H0X / Choline
  •  go-up   go-down


81. Gattoni M, Tiberio R, Angeli L, Bornacina G, Boggio P, Annali G, Giacalone A, Cristina S, Leigheb G: [Dermatofibrosarcoma protuberans: surgical treatment using the Tübingen technique (31 cases)]. Ann Dermatol Venereol; 2007 Jan;134(1):31-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Dermatofibrosarcome de Darier-Ferrand: traitement par la technique chirurgicale de Tübingen (31 cas).
  • An immunohistochimical study was performed and screening was carried out for possible extension of the neoplasm into muscle.
  • RESULTS: Muscular involvement was seen in 4 cases.
  • DISCUSSION: The Mohs technique is the surgical method of reference and allows tumour eradication with sparing of healthy tissue.
  • [MeSH-major] Dermatofibrosarcoma / surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Dermatofibrosarcoma Protuberans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Dermatol Venereol. 2007 Jan;134(1):20-1 [17384537.001]
  • (PMID = 17384539.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Kojima M, Ishii G, Yamane Y, Nishizawa Y, Saito N, Ochiai A: Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy. Pathol Int; 2009 Dec;59(12):857-62
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Area of residual tumor beyond the muscular layer is a useful predictor of outcome in rectal cancer patients who receive preoperative chemoradiotherapy.
  • The purpose of the present study was to determine whether the amount and the location of residual tumor are associated with outcome in surgically treated rectal cancer patients who receive preoperative chemoradiation therapy.
  • The total area of residual tumors was measured using morphometry software, and then the area of the residual tumors located within and beyond the muscular layer was also determined.
  • The results showed that the total area of residual tumor and area of residual tumor within the muscular layer were associated with TNM stage, tumor regression, and microscopy features, but not with patient disease-free survival.
  • The area of the residual tumor located beyond the muscular layer was significantly associated with pathological ypT, ypN stage, tumor downstaging, perineural invasion, and the depth of tumor invasion beyond the muscular layer (P < 0.05).
  • Further, large residual tumor area beyond the muscular layer was associated with shorter disease-free survival (P < 0.05).
  • Morphometry of residual tumor area beyond the muscular layer is a new pathological prognostic factor for rectal cancer patients receiving preoperative chemoradiation therapy.
  • [MeSH-major] Neoplasm, Residual / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Digestive System Surgical Procedures. Female. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Prognosis. Radiotherapy. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021610.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


83. Dalainas I: Vascular smooth muscle tumors: review of the literature. Int J Surg; 2008 Apr;6(2):157-63

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular smooth muscle tumors: review of the literature.
  • Vascular smooth muscle tumors are very rare.
  • Intravascular leiomyomatosis is a benign neoplasm that extends through the veins and caries significant morbidity.
  • Angioleiomyoma is a benign neoplasm of the extremities that caries minimal morbidity.
  • Vascular leiomyosarcomas are malign neoplasms derived from vascular smooth cells.
  • This study reviews literature for epidemiology, clinical presentation, diagnosis and management of patients with vascular smooth muscle tumors.
  • [MeSH-major] Neoplasms, Muscle Tissue / diagnosis. Neoplasms, Muscle Tissue / therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17531562.001).
  • [ISSN] 1743-9159
  • [Journal-full-title] International journal of surgery (London, England)
  • [ISO-abbreviation] Int J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 70
  •  go-up   go-down


84. Fonseca IB, Spitale LS, Gramática L, Cejas H, Piccinni DJ, Ghirardi G: [Gastrointestinal stromal tumors: conceptual evolution]. Rev Fac Cien Med Univ Nac Cordoba; 2006;63(1):37-45
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gastrointestinal stromal tumors: conceptual evolution].
  • Gastrointestinal stromal tumors (GISTs) constitute the largest category of primary nonepithelial neoplasms of the stomach and small bowel.
  • They represent about 1-2% from all neoplasms of the digestive tract.
  • They occur most commonly in the stomach and small bowel, but small series of comparable tumors have also been reported in all the other parts of the tubular gastrointestinal tract, including esophagus, colon, rectum and anus.
  • They can also involve omentum, mesentery, uterus, retroperitoneum, mesocolon and soft tissues.
  • Originally recognized in 1960 by Martin et. al. as a distinctive type of stromal neoplasm of the bowel, they were subsequently reported by Stout, who introduced the term leiomyoblastoma.
  • Because of difficulties in accurately predicting the biologic behavior of these tumors, the term "smooth muscle tumor of uncertain malignant potential" (SMTUMP) has been introduced for borderline tumors.
  • In 1983, Mazur and Clark coined the term gastrointestinal stromal tumor and suggested that these neoplasms might arise from the myenteric nervous system.
  • Some studies have reported evidence of neuronal cell differentiation in a proportion of GISTs and the term "gastrointestinal autonomic nerve tumor (GANT) has been introduced.
  • Kindblom et al are providing cogent arguments to suggest that GISTs show differentiation toward interstitial Cajal cells (pacemaker cells of the gastrointestinal tract).
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639807.001).
  • [ISSN] 0014-6722
  • [Journal-full-title] Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)
  • [ISO-abbreviation] Rev Fac Cien Med Univ Nac Cordoba
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Argentina
  • [Number-of-references] 46
  •  go-up   go-down


85. Comunoğlu NU, Durak H, Comunoğlu C, Ekici AI, Ozkan F, Akyildiz EU, Ilvan S, Calay Z, Molinas N: Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis. APMIS; 2007 Jun;115(6):726-35
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cyclooxygenase-2, c-kit, progesterone and estrogen receptors in uterine smooth muscle tumors: differential diagnosis.
  • We examined the expression pattern of cyclooxygenase-2 (COX-2) and c-kit in uterine smooth muscle neoplasms and tried to determine the role of these markers in differential diagnosis.
  • Archival tissue from 64 patients with uterine smooth muscle neoplasms (20 leiomyomas (LMs), 22 atypical leiomyomas (ALMs), and 22 leiomyosarcomas (LMSs)) was immunostained with antibodies against estrogen (ER) and progesterone receptors (PR), COX-2 and c-kit.
  • COX-2 expression in smooth muscle tumors is not a prominent feature.
  • [MeSH-major] Biomarkers, Tumor / blood. Cyclooxygenase 2 / metabolism. Proto-Oncogene Proteins c-kit / metabolism. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Smooth Muscle Tumor / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Gene Expression. Humans. Immunohistochemistry. Leiomyosarcoma / chemistry. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17550381.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


86. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB: A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol; 2009 Dec;22(12):1519-31
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors.
  • Leiomyosarcomas are malignant smooth muscle tumors that occur most commonly in the gynecologic tract and soft tissue.
  • There are different diagnostic criteria of malignancy for smooth muscle tumors arising at gynecologic and soft tissue sites and they may be managed differently but determining the primary site of a smooth muscle tumor can be difficult in some cases.
  • In addition, the distinction between malignant and benign gynecologic tract smooth muscle tumors on morphologic grounds can be challenging.
  • Using a series of tissue microarrays that contain 245 cases of leiomyosarcomas (102 gynecologic) with survival data, and 49 cases of uterine leiomyoma, we examined the ability of selected immune-markers (estrogen receptor (ER) and WT1) to distinguish between leiomyosarcomas of gynecologic and nongynecologic origin.
  • In addition, we examined whether immunostains for p16, p53 and Ki-67 could distinguish between malignant and benign gynecologic smooth muscle tumors.
  • Diffuse p16 and p53 immunopositivity and high Ki-67 proliferation index, singly or in combination, yielded an overall sensitivity of 92% and specificity of 98% for distinguishing between gynecologic leiomyosarcomas and leiomyomas and can be used as indicators of malignancy for gynecologic smooth muscle tumors.
  • Although ER positivity can be used to support the gynecologic origin of a leiomyosarcomas, nuclear WT1 immunostaining is of little use.
  • [MeSH-major] Immunohistochemistry. Leiomyoma / chemistry. Leiomyosarcoma / chemistry. Muscle Neoplasms / chemistry. Muscle, Smooth / chemistry. Uterine Neoplasms / chemistry. WT1 Proteins / analysis
  • [MeSH-minor] Adult. Antibodies. Biomarkers, Tumor / analysis. Canada. Cell Nucleus / chemistry. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Diagnosis, Differential. Europe. Female. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Male. Middle Aged. Predictive Value of Tests. Receptors, Estrogen / analysis. Sensitivity and Specificity. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. United States

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734847.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112270
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins
  •  go-up   go-down


87. Bodner-Adler B, Nather A, Bodner K, Czerwenka K, Kimberger O, Leodolter S, Mayerhofer K: Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study. Gynecol Oncol; 2006 Oct;103(1):186-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of thrombospondin 1 (TSP 1) in patients with uterine smooth muscle tumors: an immunohistochemical study.
  • OBJECTIVE: Angiogenesis is an essential component for tumor development regulated by both proangiogenic and antiangiogenic factors.
  • The aim of this study was to compare the expression of TSP 1 in cases with leiomyoma, uterine smooth muscle tumor of uncertain malignant potential (STUMP) and leiomyosarcoma (LMS).
  • METHODS: TSP 1 expression was investigated by immunohistochemistry from paraffin-embedded tissue in 26 patients with leiomyoma, in 24 patients with STUMP and in 21 patients with LMS.
  • Standard immunohistochemical techniques were used to study the expression of TSP 1 in 5-mum-thick tumor sections.
  • Furthermore, a statistically significant correlation between vascular space involvement and TSP 1 expression was observed in patients with uterine LMS, with patients without vascular space involvement having more frequently TSP 1 positive tumors (P = 0.04).
  • No statistically significant correlation between TSP 1 and clinical stage, age and recurrence disease could be detected (P > 0.05).
  • Further clinical studies are necessary to prove our results and to clarify the role of TSP 1 in uterine smooth muscle tumors.
  • [MeSH-major] Leiomyoma / metabolism. Leiomyosarcoma / metabolism. Smooth Muscle Tumor / metabolism. Thrombospondin 1 / biosynthesis. Uterine Neoplasms / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Neovascularization, Pathologic / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595146.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thrombospondin 1
  •  go-up   go-down


88. Al Hussain T, Haleem A, Alsaad KO: Synchronous hepatic, mesenteric and pulmonary Epstein-Barr virus-associated smooth muscle tumors in a renal transplant recipient. Clin Transplant; 2010 Sep-Oct;24(5):579-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous hepatic, mesenteric and pulmonary Epstein-Barr virus-associated smooth muscle tumors in a renal transplant recipient.
  • Epstein-Barr virus-associated smooth muscle tumors (EBV-SMT) are distinct lesions that occur in immunocompromised patients.
  • This report describes a synchronous and multicentric development of EBV-SMT in liver, mesentery, and lung of a 33-yr-old male patient, 10 yr after a deceased allograft renal transplantation.
  • The hepatic and mesenteric tumors were available for study.
  • These tumors were composed of bland looking, desmin-positive, spindle-shaped cells which showed a strong nuclear staining for EBV with in situ hybridization technique.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Mesentery / pathology. Neoplasms, Multiple Primary / pathology. Peritoneal Neoplasms / pathology. Smooth Muscle Tumor / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Herpesvirus 4, Human / isolation & purification. Humans. Immunoenzyme Techniques. Kidney Failure, Chronic / surgery. Kidney Transplantation. Laparotomy. Male. Tomography, X-Ray Computed. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20156224.001).
  • [ISSN] 1399-0012
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Ben Slama L, Zaghbani A, Hidaya S: [Jaw muscle tumors]. Rev Stomatol Chir Maxillofac; 2009 Dec;110(6):335-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Jaw muscle tumors].
  • [Transliterated title] Tumeurs musculaires des mâchoires.
  • Muscular tumors are rare.
  • The diagnosis is based on histopathological features.
  • Surgical excision is the recommended treatment, conservative for leiomyoma, radical for other malignant tumors.
  • [MeSH-major] Masticatory Muscles / pathology. Muscle Neoplasms / diagnosis. Neoplasms, Muscle Tissue / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Leiomyoma / diagnosis. Leiomyosarcoma / diagnosis. Rhabdomyosarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Stomatol Chir Maxillofac. 2010 Apr;111(2):119. Zoghbani, A [corrected to Zaghbani, A]
  • (PMID = 19836039.001).
  • [ISSN] 1776-257X
  • [Journal-full-title] Revue de stomatologie et de chirurgie maxillo-faciale
  • [ISO-abbreviation] Rev Stomatol Chir Maxillofac
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


90. Lax S: [Mesenchymal uterine tumors. Leiomyomas]. Pathologe; 2009 Jul;30(4):274-83
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mesenchymal uterine tumors. Leiomyomas].
  • [Transliterated title] Mesenchymale Uterustumoren. Leiomyogene Tumoren.
  • Leiomyomas are by far the most frequent mesenchymal uterine neoplasms.
  • Leiomyoma variants refer to a particular histological differentiation and growth pattern, respectively.
  • To assess malignancy, an algorithm is used based on the presence or absence of cellular atypia, tumor cell necrosis and mitosis.
  • The differential diagnosis of leiomyosarcoma includes cellular and mitotically active leiomyoma and leiomyoma with extensive infarct type necrosis (apoplectic leiomyoma).
  • The term smooth muscle tumor of uncertain malignant potential (STUMP) should be reserved for tumors with uncertainty regarding cell type, type of necrosis and mitotic index, as well as for special cases of myxoid and epithelioid smooth muscle neoplasms.
  • Immunohistochemically, the expression of desmin and caldesmon is indicative of smooth muscle tumors, while stromal tumors can express smooth muscle actin and, rarely, desmin in addition to CD10.
  • [MeSH-major] Leiomyoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Actins / biosynthesis. Calmodulin-Binding Proteins / biosynthesis. Cell Differentiation. Cell Division. Desmin. Diagnosis, Differential. Female. Humans. Leiomyosarcoma / pathology. Mitosis. Mitotic Index. Necrosis. Neprilysin / biosynthesis. Smooth Muscle Tumor / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19495761.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Actins; 0 / Calmodulin-Binding Proteins; 0 / Desmin; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


91. Tai WC, Chuah SK, Lin JW, Chen HH, Huang HY, Kuo CM, Yi LN, Lee CM, Changchien CS, Hu TH: Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors. Oncol Rep; 2008 Nov;20(5):1157-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal mesenchymal tumors - from smooth muscle tumors to stromal tumors.
  • Colorectal mesenchymal tumors are rare.
  • Therefore, distinguishing between gastrointestinal stromal (GIST) and smooth muscle tumors is important.
  • This study aimed to delineate the immunophenotype and prognostic factors of 75 colorectal mesenchymal tumors.
  • Fifty-three GIST and 22 smooth muscle tumor specimens were included from 1986 to 2007.
  • Forty of 53 GIST were initially diagnosed as smooth muscle tumors and re-diagnosed as CD117 (+) GIST.
  • Immunohistochemical studies were performed with antibodies of CD117, CD34, smooth muscle actin (SMA), desmin, S-100, Ki-67 and PCNA for clinicopathologic and prognostic correlation.
  • In comparison, colorectal GIST exhibited a larger tumor size (P<0.001), higher mitotic count (P<0.001), higher cellularity (P<0.001), less spindle cell type (P=0.004), higher nuclear pleomorphism (P=0.004), and a higher NIH risk (P<0.001) than that of smooth muscle tumors.
  • For 75 mesenchymal tumors, survival analyses revealed that older patients (P=0.006), with a large tumor size (P<0.001), high mitotic count (P<0.001), increased NIH risk (P<0.001), non-spindle cell type (P<0.001), high cellularity (P=0.015), high cell pleomorphism (P<0.001), positive Ki-67 (P<0.001), high PCNA (P<0.001) and GIST (P=0.001) had a shorter disease-free survival than that of comparative groups.
  • The tumor mitotic count was the only independent prognostic factor for either mesenchymal tumors or GIST.
  • In conclusion, GIST exhibited heterogeneous characteristics and was significantly larger, more mitotic and a poorer prognostic factor than smooth muscle tumor.
  • The mitotic count is still the most valuable prognostic factor for colorectal mesenchymal tumors after KIT.
  • [MeSH-major] Gastrointestinal Stromal Tumors / pathology. Smooth Muscle Tumor / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / pathology. Middle Aged

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949416.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


92. Ong KW, Teo M, Lee V, Ong D, Lee A, Tan CS, Vathsala A, Toh HC: Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Clin Cancer Res; 2009 Sep 1;15(17):5350-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications.
  • PURPOSE: EBV-positive smooth muscle tumor (EBV+SMT) is a rare disease with no established therapy.
  • These tumors were investigated for expression of EBV latent genes with Southern blots, EBV latent antigens, mammalian target of rapamycin (mTOR), Akt, p70 S6 kinase, and vascular endothelial growth factor using immunohistochemistry, as well as methylation status of cancer-related genes using methylation-specific PCR.
  • Complete tumor regression was seen in one patient following administration of sirolimus.
  • These tumors display the full range of known EBV latent genes.
  • Methylation of RASSF1A was found in all tissue samples, whereas promoter hypermethylation of RARbeta, GSTP1, DAPK, and p14 was observed in some samples.
  • CONCLUSIONS: Our results suggest that these tumors display a EBV type III latency pattern.
  • EBV-specific immunotherapy, mTOR inhibitors, and demethylating agents are possible therapeutic options in this disease.
  • [MeSH-major] Antigens, Viral / metabolism. Epstein-Barr Virus Infections / metabolism. Herpesvirus 4, Human / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Ribosomal Protein S6 Kinases, 70-kDa / metabolism. Smooth Muscle Tumor / metabolism
  • [MeSH-minor] Adult. Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Female. Glutathione S-Transferase pi / metabolism. Humans. Kidney Transplantation. Male. Methylation. Middle Aged. Promoter Regions, Genetic. Protein Kinases / metabolism. Receptors, Retinoic Acid / metabolism. TOR Serine-Threonine Kinases. Tumor Suppressor Proteins / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19706821.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Apoptosis Regulatory Proteins; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Tumor Suppressor Proteins; 0 / Vascular Endothelial Growth Factor A; 0 / retinoic acid receptor beta; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa
  •  go-up   go-down


93. Ip PP, Cheung AN, Clement PB: Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases. Am J Surg Pathol; 2009 Jul;33(7):992-1005
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine smooth muscle tumors of uncertain malignant potential (STUMP): a clinicopathologic analysis of 16 cases.
  • BACKGROUND: The current World Health Organization classification indicates that a uterine smooth muscle tumor that cannot be histologically diagnosed as unequivocally benign or malignant should be termed "smooth muscle tumor of uncertain malignant potential" (STUMP).
  • STUMPs represent a heterogeneous group of rare tumors that have been the subject of only a few published studies, some of which lack detailed clinicopathologic details and/or follow-up data.
  • More recently, it has been suggested that immunohistochemical staining may be helpful in the diagnosis of STUMPs.
  • DESIGN: The clinicopathologic features of 16 cases of STUMP that exhibited usual smooth muscle differentiation, diagnosed between 1992 and 2006 from 11 hospitals, were studied and classified into 4 subgroups using terminology and criteria described by Stanford investigators.
  • RESULTS: The tumors were classified as follows: 6 as "atypical leiomyoma with limited experience", 7 as "smooth muscle tumor of low malignant potential", 2 as "atypical leiomyoma, low risk of recurrence," and 1 as "mitotically active leiomyoma, limited experience."
  • Only 2 tumors recurred, at 15 and 51 months, respectively; both were atypical leiomyoma with limited experience (multifocal moderate-to-severe atypia, no tumor cell necrosis, and mitotic counts of 4 and 5 mitotic figures /10 high-power fields, respectively).
  • Both tumors had areas that were indistinguishable from benign leiomyoma and both had diffuse immunoreactivity for p16 and p53.
  • Six other tumors that had focal staining for these markers all had a benign outcome.
  • All the other patients were alive and disease-free.
  • CONCLUSIONS: This and other studies suggest that uterine tumors classified as STUMPs using criteria proposed by Stanford investigators are usually clinically benign but should be considered tumors of low malignant potential because they can occasionally recur, in some cases, years after hysterectomy.
  • After a mean follow-up of 80.8 months, only 2 of 16 tumors in this study recurred.
  • Both of the latter tumors fulfilled the criteria for atypical leiomyoma with limited experience.
  • Notably, the 2 recurrent tumors were the only ones that were strongly immunoreactive for p16 and p53, supporting earlier observations that these markers may be helpful in the prediction of the behavior of STUMPs.
  • [MeSH-major] Smooth Muscle Tumor / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Ubiquitin-Protein Ligases / biosynthesis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417585.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


94. Horton SC, Nay S, Gonzales M, McIntosh M, Hammond E, Clayson S: Smooth muscle neoplasm presenting as intrapericardial myxoma. J Am Soc Echocardiogr; 2006 Jun;19(6):835.e1-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Smooth muscle neoplasm presenting as intrapericardial myxoma.
  • The tumor was a globular mass attached to the left atrium by a stalk, suggestive of a myxoma.
  • Histology revealed a smooth muscle tumor with extensive adipocytic differentiation and numerous small blood vessels.
  • This study represents the first echocardiographic description of a smooth muscle tumor presenting as an extracardiac myxoma.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Muscle Neoplasms / ultrasonography. Muscle, Smooth, Vascular / ultrasonography. Myxoma / ultrasonography
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16762765.001).
  • [ISSN] 1097-6795
  • [Journal-full-title] Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
  • [ISO-abbreviation] J Am Soc Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Solomon LA, Schimp VL, Ali-Fehmi R, Diamond MP, Munkarah AR: Clinical update of smooth muscle tumors of the uterus. J Minim Invasive Gynecol; 2005 Sep-Oct;12(5):401-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical update of smooth muscle tumors of the uterus.
  • Smooth muscle tumors of the uterus represent a spectrum of diseases that range from benign leiomyoma to malignant leiomyosarcoma.
  • The leiomyoma is the most common of these neoplasms.
  • Clinically, it is important to fully understand the differences in clinical presentation, biologic behavior, and management for patients with benign leiomyoma, smooth muscle tumors of uncertain malignant potential, and leiomyosarcoma.
  • The goal of this review is to present the most recent information about common smooth muscle tumors of the uterus including their etiology, histopathology, radiographic and clinical presentations, and available treatment options.
  • [MeSH-major] Smooth Muscle Tumor / surgery. Uterine Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16213425.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


96. Ilha MR, Newman SJ, van Amstel S, Fecteau KA, Rohrbach BW: Uterine lesions in 32 female miniature pet pigs. Vet Pathol; 2010 Nov;47(6):1071-5
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 24 remaining pigs had diffuse cystic endometrial hyperplasia, of which 14 had smooth muscle tumors, including leiomyomas and leiomyosarcomas, in the uterus or broad ligament.
  • Nodular endometrial lesions-including adenocarcinomas, adenomas, and/or adenomyosis-were present in 10 pigs, 3 of which had concurrent smooth muscle tumors.
  • Regardless of malignancy, more than 50% of nuclei in smooth muscle tumors expressed estrogen receptor and progesterone receptor.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / veterinary. Adenoma / pathology. Adenoma / veterinary. Animals. Broad Ligament / pathology. Endometrial Hyperplasia / pathology. Endometrial Hyperplasia / veterinary. Endometrium / pathology. Estrogens / blood. Female. Leiomyoma / pathology. Leiomyoma / veterinary. Leiomyosarcoma / pathology. Leiomyosarcoma / veterinary. Progesterone / blood. Pyometra / pathology. Pyometra / veterinary. Swine. Uterine Neoplasms / pathology. Uterine Neoplasms / veterinary. Uterus / pathology

  • MedlinePlus Health Information. consumer health - Uterine Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20817893.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Estrogens; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


97. Friedman JE, Kirwan JP, Jing M, Presley L, Catalano PM: Increased skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum. Diabetes; 2008 Mar;57(3):606-13
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased skeletal muscle tumor necrosis factor-alpha and impaired insulin signaling persist in obese women with gestational diabetes mellitus 1 year postpartum.
  • Skeletal muscle biopsies were obtained at each visit, and insulin resistance was determined by the hyperinsulinemic-euglycemic clamp technique.
  • Body weight, fat mass, fasting glucose, and plasma tumor necrosis factor (TNF)-alpha remained higher 1 year postpartum than seen in previously studied normal glucose-tolerant women.
  • Skeletal muscle TNF-alpha mRNA was elevated five- to sixfold in GDM women and remained higher 1 year postpartum.
  • The levels of (312)Ser-IRS-1 also did not improve postpartum and correlated with TNF-alpha mRNA (r(2) = 0.19, P < 0.03), consistent with a state of subclinical inflammation and chronic skeletal muscle insulin resistance.
  • CONCLUSIONS: These results suggest the mechanisms underlying chronic insulin resistance in GDM women may be driven by increased inflammation that impinges on the IR and IRS-1 signaling cascade in skeletal muscle.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Obesity.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18083784.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK048520; United States / NCATS NIH HHS / TR / KL2 TR000440; United States / NCRR NIH HHS / RR / RR-00080; United States / NICHD NIH HHS / HD / R01 HD022965; United States / NICHD NIH HHS / HD / HD-11089; United States / NIDDK NIH HHS / DK / DK-62115; United States / NCRR NIH HHS / RR / M01 RR000080
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 0 / Tumor Necrosis Factor-alpha
  • [Other-IDs] NLM/ NIHMS747180; NLM/ PMC4697130
  •  go-up   go-down


98. Petrović D, Babić D, Forko JI, Martinac I: Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value. Coll Antropol; 2010 Mar;34(1):93-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Ki-67, P53 and progesterone receptors in uterine smooth muscle tumors. Diagnostic value.
  • Aim was to investigate expression of Ki-67, P53 and progesterone receptors (PR) in leiomyomas (LM), smooth muscle tumors of uncertain malignant potential (STUMP) and leiomyosarcomas (LMS) and to establish possible usefulness of these three parameters in distinguishing between LM and STUMP and STUMP and LMS.
  • Retrospective study of 51 uterine smooth muscle neoplasm (16 LM, 18 STUMP, 17 LMS) technically acceptable for analyses from years 2002-2007 from Department of Gynecological and Prenatal Pathology, University Hospital Center Zagreb, Croatia.
  • The findings of our study in concordance with other study results are helpful information establishing more diagnostic criteria and parameters for diagnosis in doubtful cases between three entities.
  • The panel of their expression in specific case eases diagnosis.
  • [MeSH-major] Ki-67 Antigen / metabolism. Leiomyoma / pathology. Leiomyosarcoma / pathology. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Count. Female. Humans. Immunohistochemistry. Muscle, Smooth / metabolism. Muscle, Smooth / pathology. Myometrium / metabolism. Myometrium / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437637.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Progesterone; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


99. Penna F, Bonetto A, Muscaritoli M, Costamagna D, Minero VG, Bonelli G, Rossi Fanelli F, Baccino FM, Costelli P: Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved? Int J Cancer; 2010 Oct 1;127(7):1706-17
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Muscle atrophy in experimental cancer cachexia: is the IGF-1 signaling pathway involved?
  • Skeletal muscle wasting, one of the main features of cancer cachexia, is associated with marked protein hypercatabolism, and has suggested to depend also on impaired IGF-1 signal transduction pathway.
  • In the skeletal muscle of tumor hosts, the levels of phosphorylated (active) Akt, one of the most relevant kinases involved in the IGF-1 signaling pathway, were comparable to controls, or even increased.
  • In the attempt to force the metabolic balance toward anabolism, IGF-1 was hyperexpressed by gene transfer in the tibialis muscle of the C26 hosts.
  • In healthy animals, IGF-1 overexpression markedly increased both fiber and muscle size.
  • As a positive control, IGF-1 was also overexpressed in the muscle of aged mice.
  • In IGF-1 hyperexpressing muscles the fiber cross-sectional area definitely increased in both young and aged animals, while, by contrast, loss of muscle mass or reduction of fiber size in mice bearing the C26 tumor were not modified.
  • These results demonstrate that muscle wasting in tumor-bearing animals is not associated with downregulation of molecules involved in the anabolic response, and appears inconsistent, at least, with reduced activity of the IGF-1 signaling pathway.
  • [MeSH-major] Cachexia / etiology. Carcinoma, Hepatocellular / complications. Insulin-Like Growth Factor I / physiology. Muscular Atrophy / etiology
  • [MeSH-minor] Animals. Electroporation / methods. Forkhead Transcription Factors / metabolism. Gene Expression Regulation. Liver Neoplasms / complications. Liver Neoplasms / pathology. Male. Mice. Mice, Inbred BALB C. Plasmids. Polymerase Chain Reaction. Rats. Rats, Wistar. Signal Transduction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20039316.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 67763-96-6 / Insulin-Like Growth Factor I
  •  go-up   go-down


100. Gallien S, Zuber B, Polivka M, Lagrange-Xelot M, Thiebault JB, Bertheau P, Gray F, Molina JM: Multifocal Epstein-Barr virus-associated smooth muscle tumor in adults with AIDS: case report and review of the literature. Oncology; 2008;74(3-4):167-76
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal Epstein-Barr virus-associated smooth muscle tumor in adults with AIDS: case report and review of the literature.
  • OBJECTIVES: The aim of this study was to provide a systematic review of Epstein-Barr virus-associated smooth muscle tumors (EBV-SMT) in human immunodeficiency virus (HIV)-infected adults, focusing on clinical and histopathologic features and outcome.
  • RESULTS: We reviewed 35 cases including our case of a patient with a progressive multifocal EBV-SMT.
  • The tumors were multifocal in 34% of cases, whereas analysis of clonality showed different clones in tumors from different sites.
  • Mean follow-up after diagnosis was 12.3 months.
  • Nine patients died during this period essentially from opportunistic infection and only 2 from the disease.
  • CONCLUSION: EBV-SMT should be added to the list of virally induced tumors in severely immunocompromised HIV-infected adults.
  • Multifocality of independent tumor clones, especially in liver, brain, spinal cord and adrenal gland, and a slow disease progression seem to be the key features of these tumors, the treatment of which remains poorly defined.
  • [MeSH-major] AIDS-Related Opportunistic Infections / virology. Epstein-Barr Virus Infections / virology. Sarcoma / virology. Smooth Muscle Tumor / virology
  • [MeSH-minor] Adult. CD4 Lymphocyte Count. HIV Infections / genetics. HIV Infections / virology. HIV-1 / genetics. HIV-1 / isolation & purification. Herpesvirus 4, Human / genetics. Herpesvirus 4, Human / isolation & purification. Humans. Magnetic Resonance Imaging. Male. RNA, Viral / genetics. Tomography, X-Ray Computed. Tuberculoma, Intracranial / diagnosis. Tuberculosis / complications. Tuberculosis / diagnosis. Tuberculosis / therapy

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18714165.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down






Advertisement